<SEC-DOCUMENT>0001558370-24-006478.txt : 20240502
<SEC-HEADER>0001558370-24-006478.hdr.sgml : 20240502
<ACCEPTANCE-DATETIME>20240502110852
ACCESSION NUMBER:		0001558370-24-006478
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240502
FILED AS OF DATE:		20240502
DATE AS OF CHANGE:		20240502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		24906296

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>gmab-20240502x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/29/2024 03:44:47 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF MAY 2024</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Carl Jacobsens Vej 30</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2500 Valby</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background:#ffffff;">Exhibit 99.1 to this report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background:#ffffff;">&#160;in Genmab A/S&#8217;s registration statement on&#160;</font><font style="background:#ffffff;">Form&#160;S-8</font><font style="background:#ffffff;">&#160;(File&#160;No. 333-232693, </font>333-253519, 333-262970 and 333-277273<font style="background:#ffffff;">)&#160;and in the outstanding prospectus contained in such registration statement. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: May 2, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:96.42%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">A</b></p></div></div></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">99.1</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Interim Report Dated May 2, 2024</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gmab-20240502xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/29/2024 03:44:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title>Interim Report for the 6 months ended June 30, 2011</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">May 2, 2024 Copenhagen, Denmark; </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Interim Report for the First Quarter Ended March 31, 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Highlights</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">An additional Phase 3 clinical trial was initiated, evaluating epcoritamab in combination with rituximab and lenalidomide compared to chemoimmunotherapy in previously untreated follicular lymphoma </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">The U.S. FDA accepted for Priority Review the sBLA seeking to convert the accelerated approval of Tivdak</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab announced the decision of its arbitration appeal under its daratumumab license agreement with Janssen Biotech, Inc. (Janssen)</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab revenue increased 46% compared to the first quarter of 2023, to DKK 4,143 million</b></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk12956096"></a>&#8220;The acceptance for Priority Review by the U.S. FDA of the sBLAs for EPKINLY and Tivdak that we received in the first quarter are important events that support our commitment to continue to deliver innovative treatment options that have the potential to profoundly impact the lives of patients. These regulatory acceptances for priority review also reflect our dedication to working with our partners, AbbVie Inc. (AbbVie) and Pfizer Inc. (Pfizer) to expand the labels for EPKINLY and Tivdak, respectively, in order to maximize the potential of both medicines and bring them to as many patients in need of alternative therapeutic options as possible,&#8221; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="background:#ffff00;"> </font><font style="visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Financial Performance First Quarter of 2024</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenue was DKK 4,143 million for the first three months of 2024 compared to DKK 2,834 million for the first three months of 2023. The increase of DKK 1,309 million, or 46%, was primarily driven by higher DARZALEX</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> and Kesimpta</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> royalties achieved under our collaborations with Janssen and Novartis Pharma AG (Novartis), respectively, EPKINLY net product sales, and a milestone achieved under our collaboration with AbbVie.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Royalty revenue was DKK 3,104 million in the first three months of 2024 compared to DKK 2,408 million in the first three months of 2023, an increase of DKK 696 million, or 29%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">FASPRO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the U.S.) by Janssen were USD 2,692 million in the first three months of 2024 compared to USD 2,264 million in the first three months of 2023, an increase of USD 428 million or 19%.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Hlk527456303"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total costs and operating expenses were DKK 3,342 million in the first three months of 2024 compared to DKK 2,417 million in the first three months of 2023. The increase of DKK 925 million, or 38%, was driven by the </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of our product pipeline, EPKINLY post launch </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">activities in the U.S. and Japan, the continued development of Genmab&#8217;s broader organizational capabilities and related increase in team members to support these activities, as well as profit-sharing amounts payable to AbbVie related to EPKINLY sales.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="OLE_LINK13"></a><a name="OLE_LINK14"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating profit was DKK 801 million in the first three months of 2024 compared to DKK 417 million in the first three months of 2023</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Hlk164842825"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net financial items resulted in income of DKK 915 million for the first three months of 2024 compared to an expense of DKK 151 million in the first three months of 2023. The increase of DKK 1,066 million was primarily driven by movements in USD to DKK foreign exchange rates impacting Genmab&#8217;s USD denominated cash and cash equivalents and marketable securities, with strengthening of the USD/DKK rate in the first three months of 2024 compared to the weakening of the USD/DKK rate in the first three months of 2023.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Subsequent Event</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">April: </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Genmab and ProfoundBio, Inc. (ProfoundBio) announced that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. The acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio&#8217;s novel antibody-drug conjugate (ADC) technology platforms. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio&#8217;s closing net debt and transaction expenses). The proposed transaction is expected to close in the first half of 2024. The closing of the proposed transaction is subject to the satisfaction of customary closing conditions.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Outlook</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is maintaining its 2024 financial guidance published on February 14, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Following the announcement of the proposed acquisition of ProfoundBio, Genmab&#8217;s operating expenses before expenses incurred by it in connection with the proposed transaction are now anticipated to be at or moderately above the upper end of the previously disclosed guidance range of DKK 12.4 -13.4 billion. The anticipated increase reflects the incremental R&amp;D investment to support the advancement of ProfoundBio&#8217;s clinical programs, primarily Rina-S. Genmab&#8217;s revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 &#8211; 20.5 billion. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect to update our guidance no later than in connection with our second quarter 2024 earnings.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:20.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:28.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Conference Call</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab will hold a conference call to discuss the results for the first quarter of 2024 today, Thursday, May 2, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: <font style="color:#029c93;">https://register.vevent.com/register/BIcaf0da755ddb4d7f81f4dd2c0229135e</font>. A live and archived webcast of the call and relevant slides will be available at <font style="color:#029c93;">www.genmab.com/investors</font>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Contact</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marisol Peron, Senior Vice President, Global Communications &amp; Corporate Affairs</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +1 609 524 0065; E: <font style="color:#029c93;">mmp@genmab.com</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Andrew Carlsen, Vice President, Head of Investor Relations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +45 3377 9558; E: <font style="color:#029c93;">acn@genmab.com</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">CONTENTS</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><b style="color:#029c93;font-weight:bold;">MANAGEMENT&#8217;S REVIEW</b></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#CONSOLIDATEDKEYFIGURES_439617"><font style="font-style:normal;font-weight:normal;">CONSOLIDATED KEY FIGURES</font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#OUTLOOK_182548"><font style="font-style:normal;font-weight:normal;">OUTLOOK</font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#KEY2019PRIORITIES_328557"><font style="font-style:normal;font-weight:normal;">KEY 2024 PRIORITIES</font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#PRODUCTPIPELINE_603298"><font style="font-style:normal;font-weight:normal;">PRODUCT PIPELINE</font></a> <a href="#PRODUCTPIPELINE_603298"><font style="font-style:normal;font-weight:normal;">AND TECHNOLOGY PROGRESS FIRST QUARTER OF 2024 </font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#_SIGNIFICANT_RISKS_AND"><font style="font-style:normal;font-weight:normal;">SIGNIFICANT RISKS AND UNCERTAINTIES</font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#FINANCIALREVIEW_601130"><font style="font-style:normal;font-weight:normal;">FINANCIAL REVIEW</font></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#Statementsofcomprehensiveincome"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">FINANCIAL STATEMENTS</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#NOTESTOTHEFINANCIALSTATEMENTS_435403"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTES&#160;TO THE FINANCIAL STATEMENTS</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#ABOUTGENMAB_556806"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">ABOUT GENMAB</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">DIRECTORS&#8217; AND MANAGEMENT&#8217;S STATEMENT ON THE INTERIM REPORT</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">38</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 3/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">CONSOLIDATED KEY FIGURES</b><b style="font-size:16pt;font-weight:bold;"><a name="_MON_1428392831"></a></b><b style="color:#339966;font-weight:bold;white-space:pre-wrap;">   </b><b style="font-size:16pt;font-weight:bold;"><a name="CONSOLIDATEDKEYFIGURES_439617"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Full Year</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,143</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,834</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 16,474</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cost of product sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (185)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (226)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,300)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,741)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,630)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (857)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (676)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,297)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Total costs and operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,342)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,417)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,153)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Operating profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 801</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 417</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,321</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net financial items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 915</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (151)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 316</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,325</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 210</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,352</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,914</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,256</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,268</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,670</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,288</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,867</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,311</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,163</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,150</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 36,680</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 30,219</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 35,289</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shareholders&#39; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32,497</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 27,015</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 31,610</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Cash Flow Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,513</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,235</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,380</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,441)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,282)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (595)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (611)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (606)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Investment in intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (10)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (28)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (104)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (366)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Financial Ratios and Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Basic net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 20.29</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3.21</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66.64</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Diluted net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 20.18</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3.19</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66.02</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Period-end share market price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,084</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,589</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,155</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Price / book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4.23</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6.33</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4.50</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shareholders&#39; equity per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 492.38</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 409.32</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 478.94</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Equity ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 89</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 89</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 90</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">66,122,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 65,985,932</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66,074,535</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Average number of employees (FTE*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,266</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,795</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,011</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Number of employees (FTE) at the end of the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,286</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,846</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,204</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><font style="white-space:pre-wrap;">* Full-time equivalent or team members  </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 4/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Toc16514641"></a><b style="color:#029c93;font-size:11pt;font-weight:bold;">OUT</b><a name="_Hlk117861578"></a><a name="_Hlk117854937"></a><b style="color:#029c93;font-size:11pt;font-weight:bold;">LOOK</b><b style="color:#029c93;font-size:11pt;font-weight:bold;"> </b><a name="OUTLOOK_182548"></a><a name="_Hlk22722517"></a><a name="_Hlk117861572"></a><a name="_Hlk117854930"></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">18,700 - 20,500</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;white-space:pre-wrap;"> Royalties</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">15,600 - 16,700</i></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;white-space:pre-wrap;"> Net product sales/Collaboration revenue*</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">1,700 - 2,200</i></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><i style="font-style:italic;white-space:pre-wrap;"> Milestones/Reimbursement revenue</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;background:#f2f2f2;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">1,400 - 1,600</i></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross profit**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">18,000 - 19,500</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating expenses**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(12,400) - (13,400)</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4,600 - 7,100</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">*Net Product Sales and Collaboration Revenue consists of EPKINLY Net Product Sales in the U.S. and Japan and Tivdak (Genmab&#8217;s share of net profits) in the U.S.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">**Operating Expenses Range excludes Cost of Product Sales Range, which is included in Gross Profit Range</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is maintaining its 2024 financial guidance published February 14, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Following the announcement of the proposed acquisition of ProfoundBio, Genmab&#8217;s operating expenses before expenses incurred by it in connection with the proposed transaction are now anticipated to be at or moderately above the upper end of the previously disclosed guidance range of DKK 12.4 -13.4 billion. The anticipated increase reflects the incremental R&amp;D investment to support the advancement of ProfoundBio&#8217;s clinical programs, primarily Rina-S. Genmab&#8217;s revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 &#8211; 20.5 billion. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect to update our guidance no later than in connection with our second quarter 2024 earnings.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab expects its 2024 revenue to be in the range of DKK 18.7 &#8211; 20.5 billion, compared to DKK 16.5 billion in 2023. Our revenue in 2023 was driven primarily by DARZALEX royalties due to the continued strong growth of DARZALEX net sales, partially offset by negative exchange rate movements between the USD and DKK and the negative impact of applying the DARZALEX contractual annual Currency Hedge Rate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s projected revenue growth for 2024 is driven by higher royalties, net product sales and collaboration revenue. Royalty growth relates mainly to DARZALEX and Kesimpta net sales growth. Net product sales and collaboration revenue growth are driven by strong performance for both Tivdak and EPKINLY. Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (50% gross profit share) in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s projected revenue for 2024 primarily consists of DARZALEX royalties of DKK 12.6 &#8211; 13.3 billion. Such royalties are based on estimated DARZALEX 2024 net sales of USD 10.9 &#8211; 11.5 billion compared to actual net sales in 2023 of approximately USD 9.7 billion. DARZALEX royalties are partly offset by Genmab&#8217;s share of Janssen&#8217;s royalty payments to Halozyme Therapeutics, Inc. (Halozyme) in connection with SC net sales as well as royalty reduction in countries and territories where there are no Genmab patents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 5/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The remainder of Genmab&#8217;s revenue consists of royalties from Kesimpta, TEPEZZA<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, RYBREVANT<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, TECVAYLI<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, TALVEY<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup> and TEPKINLY<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, net product sales and collaboration revenue from EPKINLY/TEPKINLY and Tivdak, reimbursement revenue and milestones.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk117861601"></a><b style="color:#029c93;font-weight:bold;">Operating Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab anticipates its 2024 operating expenses to be in the range of DKK 12.4 &#8211; 13.4 billion, compared to DKK 10.9 billion in 2023. The growth in operating expenses is to support Genmab&#8217;s continued portfolio advancement and investing for future product launches, including epcoritamab.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Operating Profit</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab expects its 2024 operating profit to be in the range of DKK 4.6 &#8211; 7.1 billion, compared to DKK 5.3 billion in 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Outlook: Risks and Assumptions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab&#8217;s collaboration agreements; the timing and variation of development activities (including activities carried out by Genmab&#8217;s collaboration partners) and related income and costs; DARZALEX, DARZALEX <i style="font-style:italic;">FASPRO,</i><sup style="font-size:7.5pt;font-style:italic;vertical-align:top;"> </sup> Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY and TEPKINLY net sales and royalties paid to Genmab; changing rates of inflation; and currency exchange rates (the 2024 guidance assumes a USD / DKK exchange rate of 6.8). The financial guidance assumes that no significant new agreements are entered into during the remainder of <a name="_Hlk117861623"></a>2024 that could materially affect the results. Refer to the section &#8220;Significant Risks and Uncertainties&#8221; in this interim report for matters that may cause Genmab&#8217;s actual results to differ materially from 2024 Guidance and Key 2024 Priorities in this interim report. <a name="_Hlk117854961"></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The factors discussed above, as well as other factors that are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab&#8217;s business and financial performance, including on the sales of Tivdak and EPKINLY/TEPKINLY, and on the net sales of DARZALEX, Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI and TALVEY by Genmab&#8217;s collaboration partners and on Genmab&#8217;s royalties, collaboration revenue and milestone revenue therefrom.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 0pt 0pt;"><b style="color:#029c93;font-weight:bold;">KEY 2024 PRIORITIES</b><b style="font-size:16pt;font-weight:bold;"><a name="KEY2019PRIORITIES_328557"></a></b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Bring Our Own Medicines to Patients</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">EPKINLY<sup style="font-size:7.5pt;vertical-align:top;">1</sup></p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Initiate three Phase 3 trials</font></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expand label to include relapsed/refractory FL&#160;</font></div></div></div></td></tr><tr><td style="display:none;vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tivdak<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Initiate Phase 3 study in head and neck cancer</font></div></div></div></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:top;width:49.99%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Execute successful launches and growth in key markets</p></td></tr><tr><td rowspan="3" style="vertical-align:middle;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Build World-class Differentiated Pipeline&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Acasunlimab (GEN1046/BNT311, DuoBody<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>-PD-L1x4-1BB)<sup style="font-size:7.5pt;vertical-align:top;">3</sup></p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Initiate Phase 3 study (second line non-small cell lung cancer (NSCLC))</font></div></div></div></td></tr><tr><td style="display:none;vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN1042 (DuoBody-CD40x4-1BB)<sup style="font-size:7.5pt;vertical-align:top;">3</sup></p><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 data and determine next steps </font></div></div></div></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 6/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td rowspan="1" style="vertical-align:middle;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expand and advance&#160;proprietary&#160;clinical&#160;<br>product portfolio</p></td></tr><tr><td style="vertical-align:top;width:49.99%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Invest in Our People &amp; Culture</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further scale organization aligned&#160;with&#160;<br>differentiated antibody product&#160;portfolio&#160;<br>growth and future&#160;launches</p></td></tr><tr><td style="vertical-align:top;width:49.99%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;background:#bfbfbf;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:27.4pt;"><td style="vertical-align:middle;width:49.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Become a Leading Integrated Biotech</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Innovation&#160;Powerhouse</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Use solid financial base to grow and broaden&#160;antibody product and technology portfolio</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1. Co-development w/ AbbVie; 2. Co-development w/ Pfizer; 3. Co-development w/ BioNTech</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">PRODUCT PIPELINE</b><a name="PRODUCTPIPELINE_603298"></a><b style="color:#029c93;font-weight:bold;"> AND TECHNOLOGY PROGRESS FIRST QUARTER OF 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At the end of the first quarter of 2024, Genmab&#8217;s proprietary pipeline of investigational medicines, where we are responsible for at least 50% of development, consisted of ten antibodies in clinical development. These include Genmab&#8217;s approved medicines, Tivdak, which Genmab is co-developing globally and co-promoting in the U.S. in collaboration with Pfizer, and EPKINLY/TEPKINLY, which Genmab is co-developing and co-commercializing in the U.S. and Japan in collaboration with AbbVie. In addition to our own pipeline, there are multiple investigational medicines in development by global pharmaceutical and biotechnology companies, including six approved medicines powered by Genmab&#8217;s technology and innovations. Beyond the investigational medicines in clinical development, our pipeline also includes multiple preclinical programs. An overview of the development status of our approved medicines and of each of our investigational medicines is provided in the following section, including updates for the first quarter of 2024. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen A/S (Nasdaq Copenhagen) stock exchange and may also be found in Genmab&#8217;s filings with the U.S. Securities and Exchange Commission (U.S. SEC). Additional information is available on Genmab&#8217;s website, <font style="color:#029c93;">www.genmab.com</font>. The information accessible through our website is not part of this report and is not incorporated by reference herein.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="PRODUCTPIPELINEANDTECHNOLOGYPROGRESSFIRS"></a><font style="color:#339966;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Genmab Proprietary Products</b><sup style="color:#029c93;font-size:8.25pt;font-weight:bold;vertical-align:top;">1</sup></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Approved Medicines</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-bottom:2.15pt;padding-top:2.15pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:24.85%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:24.61%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.1%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.42%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:24.85%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Approved Product</b></p></td><td style="vertical-align:top;width:24.61%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Target</b></p></td><td style="vertical-align:top;width:25.1%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Developed By</b></p></td><td style="vertical-align:top;width:25.42%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Disease Indication</b></p></td></tr><tr><td style="vertical-align:top;width:24.85%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EPKINLY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(epcoritamab-bysp, epcoritamab)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TEPKINLY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(epcoritamab)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.61%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CD3xCD20</p></td><td style="vertical-align:top;width:25.1%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Co-development</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab/AbbVie </p></td><td style="vertical-align:top;width:25.42%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Approved in multiple territories including in the U.S. and Europe for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy and in Japan for adult patients with certain types of relapsed or </p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 7/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-bottom:2.15pt;padding-top:2.15pt;width:100%;"><tr><td style="vertical-align:top;width:24.85%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"></td><td style="vertical-align:top;width:24.61%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"></td><td style="vertical-align:top;width:25.1%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"></td><td style="vertical-align:top;width:25.42%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr><td style="vertical-align:top;width:24.85%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tivdak</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(tisotumab vedotin-tftv)</p></td><td style="vertical-align:top;width:24.61%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tissue factor (TF)</p></td><td style="vertical-align:top;width:25.1%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Co-development Genmab/Pfizer </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.42%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Approved in the U.S. for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;vertical-align:top;">1</sup>Approved and investigational medicines where Genmab has &#8805;50% ownership, in co-development with partners as indicated.<br><sup style="font-size:6pt;vertical-align:top;">2</sup>Refer to relevant local prescribing information for precise indication and safety information.<br><font style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pipeline, Including Further Development for Approved Medicines</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:14pt 0pt 0pt 0pt;"><img src="gmab-20240502xex99d1005.jpg" alt="Graphic" style="display:inline-block;height:277.8pt;width:468pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">*Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="color:#029c93;font-weight:bold;">EPKINLY/TEPKINLY (epcoritamab) &#8211; Approved in territories including the U.S., Europe, and Japan</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">SC bispecific antibody created using Genmab&#8217;s DuoBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Epcoritamab (approved as EPKINLY and TEPKINLY) has received regulatory approvals in multiple territories; see local prescribing information for specific indications and safety information</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 8/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">These approvals were based on data from the relapsed/refractory LBCL cohort of the pivotal EPCORE&#8482; NHL-1 trial (NCT03625037). The approval in Japan was also based on the EPCORE NHL-3 trial (NCT04542824)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulatory submissions for epcoritamab for the treatment of relapsed/refractory FL are currently under review in the U.S., Europe, and Japan</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple clinical trials are ongoing across different settings and histologies, including four Phase 3 trials, with more trials in planning</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed and co-commercialized in collaboration with AbbVie</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Epcoritamab is a proprietary bispecific antibody created using Genmab&#8217;s DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically validated target on malignant B-cells. Genmab used technology licensed from Medarex Inc. (Medarex) to generate the CD20 antibody forming part of epcoritamab. Epcoritamab is marketed as EPKINLY in the U.S., Japan, and other regions, and as TEPKINLY in Europe and other regions. See local prescribing information for precise indications. In 2020, Genmab entered into a collaboration agreement with AbbVie to jointly develop and commercialize epcoritamab. The companies share commercialization responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab records sales in the U.S. and Japan and receives tiered royalties between 22% and 26% on remaining global sales outside of these territories, subject to certain royalty reductions. The companies have a broad clinical development program for epcoritamab including four ongoing Phase 3 trials and additional trials in planning. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font><font style="color:#029c93;"> </font>for EPKINLY and the <font style="color:#029c93;">European Summary of Product Characteristics</font><font style="color:#029c93;"> </font>for TEPKINLY for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2024 Updates</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">March: Genmab submitted a supplemental Japan New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare in Japan for SC EPKINLY for the treatment of relapsed or refractory FL after two or more lines of systemic therapy. The application was supported by data from the FL cohort of the EPCORE NHL-1 trial and the EPCORE NHL-3 trial.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">February: The U.S. FDA granted Priority Review for the sBLA for epcoritamab-bysp for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. The U.S. FDA has assigned a PDUFA target action date of June 28, 2024. The submission was supported by data from the FL cohort of the EPCORE NHL-1 trial.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">February: A new Phase 3 clinical trial was initiated, evaluating the safety and efficacy of SC epcoritamab in combination with rituximab and lenalidomide compared to chemoimmunotherapy in previously untreated FL (EPCORE FL-2, NCT06191744).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">February: Multiple data presentations, including oral presentations, at the 21st Annual Meeting of the Japanese Society of Medical Oncology (JSMO).</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Tivdak (tisotumab vedotin-tftv) &#8211; First and only U.S. FDA approved ADC for recurrent or metastatic cervical cancer</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">An ADC directed to TF, a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accelerated approval granted by the U.S. FDA for tisotumab vedotin-tftv, marketed as </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tivdak</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, as the first and only approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. FDA accelerated approval was based on data from the innovaTV 204 (NCT03438396) clinical trial </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 9/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulatory submissions for tisotumab for the treatment of recurrent or metastatic cervical cancer are currently under review in both the U.S. and in Europe, based on a </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">confirmatory Phase 3 trial (innovaTV 301, NCT04697628)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials in other solid tumors are ongoing</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed globally and co-promoted in the U.S. in collaboration with Pfizer</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 4.5pt 11pt 0pt;">Tisotumab vedotin is an ADC composed of Genmab&#8217;s human monoclonal antibody directed to TF and Pfizer&#8217;s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E to the antibody. Genmab used technology licensed from Medarex to generate the TF antibody forming part of tisotumab vedotin. Tisotumab vedotin-tftv, marketed as Tivdak, is the first and only U.S. FDA approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin is being co-developed by Genmab and Pfizer. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and will lead commercial operational activities in Japan. Pfizer is leading commercial operational activities in the U.S. and will lead commercial operational activities in Europe and China. In these four markets there will be a 50:50 profit split. In other markets, Pfizer will commercialize Tivdak and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties. The companies have joint decision-making power on the worldwide development and commercialization strategy for Tivdak. The companies have additional ongoing clinical trials for Tivdak, including a confirmatory Phase 3 trial in recurrent or metastatic cervical cancer, which is the basis of regulatory submissions in both the U.S. and in Europe. The innovaTV 301 China extension trial (ZL-1309-002, NCT05866354) is also ongoing, in collaboration with Zai Lab Limited under their agreement with Pfizer. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 4.5pt 11pt 0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> for Tivdak for the labeled indication and safety information, including the boxed warning.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">First Quarter 2024 Updates</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">March: The U.S. National Comprehensive Cancer Network</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> (NCCN</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">) updated their Clinical Practice Guidelines in Oncology for Vaginal Cancer to include tisotumab vedotin-tftv under &#8220;Other Recommended Regimens&#8221; as second-line or subsequent systemic therapy for patients with recurrent or metastatic squamous cell carcinoma/adenocarcinoma primary vaginal cancer.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">March: Multiple data presentations, including a late-breaking oral presentation, at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">February: The European Medicines Agency validated for review the marketing authorization application of tisotumab vedotin for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">January: The U.S. FDA accepted the sBLA seeking to convert the accelerated approval of Tivdak to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy. The application was granted Priority Review with a PDUFA action date of May 9, 2024.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><font style="font-weight:bold;margin-bottom:11pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Acasunlimab (GEN1046/BNT311) &#8211; Bispecific next-generation immunotherapy</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody targeting PD-L1 and 4-1BB, created using Genmab&#8217;s DuoBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials in solid tumors ongoing</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 10/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Acasunlimab (GEN1046/BNT311, DuoBody-PD-L1x4-1BB) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#8217;s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for acasunlimab on a 50:50 basis. Acasunlimab is designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation using an inert DuoBody format. Acasunlimab is currently in Phase 2 clinical development. Based on encouraging data from the Phase 2 trial in NSCLC (NCT05117242), we are engaging with health authorities to determine next steps for the program.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN1042 (BNT312) &#8211; Potential first-in-class bispecific agonistic antibody</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody targeting CD40 and 4-1BB, created using Genmab&#8217;s DuoBody technology platform </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple clinical trials in solid tumors ongoing</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>GEN1042 (DuoBody-CD40x4-1BB, BNT312) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#8217;s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1042 on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance activation of both dendritic cells and antigen-dependent T-cells. Three clinical trials of GEN1042 in solid tumors are ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN3014 &#8211; HexaBody-based investigational medicine with potential in hematological malignancies</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody targeting CD38, created using Genmab&#8217;s HexaBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical trial (NCT04824794) in relapsed/refractory multiple myeloma and other hematological malignancies ongoing </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed in an exclusive worldwide license and option agreement with Janssen</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN3014 (HexaBody-CD38) is a human CD38 monoclonal antibody-based investigational medicine created using Genmab&#8217;s HexaBody technology platform. GEN3014 is a second generation CD38 targeting lgG1 antibody with a hexamerization-enhancing modification. GEN3014 is designed to induce antitumor activity through highly potent complement-dependent cytotoxicity (CDC) and antitumor activity, which is enhanced compared to daratumumab as demonstrated in previously presented preclinical data and is effective at a wider range of target expression levels. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen to develop and commercialize GEN3014. A Phase 1/2 clinical trial in hematologic malignancies is ongoing and includes a cohort comparing GEN3014 to daratumumab in CD38 monoclonal antibody-na&#239;ve relapsed or refractory multiple myeloma patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN1047 &#8211; Bispecific antibody with potential in solid tumors</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody targeting CD3 and B7H4, created using Genmab&#8217;s DuoBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical trial </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">(NCT05180474) </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in malignant solid tumors ongoing </font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN1047 (DuoBody-CD3xB7H4) is a bispecific antibody-based investigational medicine created using Genmab&#8217;s DuoBody technology platform. B7H4 is a tumor associated antigen expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, GEN1047 </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 11/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">induced T-cell mediated cytotoxicity of B7H4-positive tumor cells. GEN1047 is being developed for the potential treatment of solid cancer indications known to express B7H4. A Phase 1/2 clinical trial of GEN1047 in malignant solid tumors is ongoing and currently in the dose-expansion phase.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN3017 &#8211; DuoBody-based investigational therapy in the clinic</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody targeting CD3 and CD30, created using Genmab&#8217;s DuoBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trial (NCT06018129) in relapsed or refractory classical Hodgkin lymphoma and NHL ongoing </font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN3017 (DuoBody-CD3xCD30) is a bispecific antibody-based investigational medicine created using Genmab&#8217;s DuoBody technology platform. CD30 is highly expressed in multiple hematologic malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. In preclinical studies, GEN3017 induced potent T-cell mediated cytotoxicity of CD30-expressing tumor cells, which was associated with induction of CD4+ and CD8+ T-cell activation, proliferation, and cytokine production. GEN3017 is being developed for the potential treatment of certain hematological malignancies. A Phase 1/2 clinical trial of GEN3017 in relapsed or refractory classical Hodgkin lymphoma and NHL is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN1053 (BNT313) &#8211; HexaBody-based investigational medicine with potential in solid tumors</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody targeting CD27, created using Genmab&#8217;s HexaBody technology platform</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical trial (NCT05435339) in solid tumors ongoing </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN1053 (HexaBody-CD27, BNT313) is a CD27 antibody that utilizes Genmab&#8217;s HexaBody technology, specifically engineered to induce CD27 clustering on T cells and thus to enhance T cell activation. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1053 on a 50:50 basis. A Phase 1/2 clinical trial of GEN1053 in solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN1059 (BNT314) &#8211; Bispecific antibody with potential in solid tumors</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody targeting EpCAM and 4-1BB, created using Genmab&#8217;s DuoBody technology platform </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical trial (NCT06150183) in solid tumors ongoing </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN1059 (DuoBody-EpCAMx4-1BB, BNT314), jointly owned by Genmab and BioNTech and created using Genmab&#8217;s DuoBody technology platform, is a proprietary bispecific antibody aimed at boosting antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity. GEN1059 is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1059 on a 50:50 basis. A Phase 1/2 clinical trial of GEN1059 in solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><b style="font-weight:bold;">First Quarter 2024 Update</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">January: The first patient was treated in the first-in-human Phase 1/2 trial of GEN1059 in advanced or metastatic solid tumors.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><font style="font-weight:bold;margin-bottom:11pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">GEN1056 (BNT322) &#8211; First-in-human trial ongoing</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trial (NCT05586321) in solid tumors ongoing </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 12/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GEN1056 (BNT322) is an antibody product being co-developed by Genmab and BioNTech for the treatment of solid tumors. A first-in-human Phase 1 clinical study of GEN1056 in patients with advanced solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Preclinical Programs</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Broad preclinical pipeline that includes both partnered products and in-house programs based on our proprietary technologies and/or antibodies</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple new Investigational New Drug (IND) applications expected to be submitted over the coming years</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our preclinical pipeline includes immune effector function enhanced antibodies developed with our HexaBody technology platform and bispecific antibodies created with our DuoBody technology platform. We are also collaborating with our partners to generate additional new antibody-based product concepts. A number of the preclinical programs are conducted in cooperation with our collaboration partners.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Programs Incorporating Genmab&#8217;s Innovation and Technology</b><sup style="font-size:7.5pt;vertical-align:top;">1</sup></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to Genmab&#8217;s own pipeline of investigational medicines, our innovations and proprietary technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical development programs with antibodies created by Genmab or created using Genmab&#8217;s proprietary DuoBody bispecific antibody technology platform. The programs run from Phase 1 development to approved medicines. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;">The information in this section includes those therapies that have been approved by regulatory agencies in certain territories. Under the agreements for these medicines Genmab is entitled to certain potential milestones and royalties.</font> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Approved Medicines</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">1</sup></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-bottom:2.15pt;padding-top:2.15pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.16%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:35.06%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:30.76%;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Approved Product</b></p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Discovered and/or Developed &amp; Marketed By</b></p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Disease Indication(s)</b></p></td></tr><tr style="height:20.6pt;"><td rowspan="2" style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">DARZALEX</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(daratumumab)/<b style="font-weight:bold;">DARZALEX </b><font style="font-style:italic;font-weight:bold;">FASPRO</font> (daratumumab and hyaluronidase-fihj) </p></td><td rowspan="2" style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen (Royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Multiple myeloma<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr style="height:20.6pt;"><td style="display:none;vertical-align:middle;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"></td><td style="display:none;vertical-align:middle;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Light-chain (AL) Amyloidosis<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 13/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-bottom:2.15pt;padding-top:2.15pt;width:100%;"><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Kesimpta</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(ofatumumab)</p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Novartis (Royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Relapsing multiple sclerosis (RMS)<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TEPEZZA</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(teprotumumab-trbw)</p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amgen Inc. (Amgen) (under sublicense from Roche, royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thyroid eye disease (TED)<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RYBREVANT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(amivantamab/amivantamab-vmjw)</p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen (Royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">NSCLC<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TECVAYLI</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(teclistamab/teclistamab-cqyv)</p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen (Royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Relapsed and refractory multiple myeloma<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr><tr><td style="vertical-align:top;width:34.16%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TALVEY </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(talquetamab/talquetamab-tgvs)</p></td><td style="vertical-align:top;width:35.06%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen (Royalties to Genmab on net global sales)</p></td><td style="vertical-align:top;width:30.76%;border-bottom:1.0pt solid #029c93;border-top:1.0pt solid #029c93;margin:0pt;padding:2.15pt 5.4pt 2.15pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Relapsed and refractory multiple myeloma<sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;margin:0pt;"><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;">1</sup>Approved and investigational medicines created by Genmab or created by collaboration partners leveraging Genmab&#8217;s DuoBody technology platform, under development, and where relevant, commercialized by a third party.<br><sup style="font-size:6pt;vertical-align:top;">2</sup>See local prescribing information for precise indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt;"><font style="font-size:8pt;margin-bottom:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pipeline, Including Further Development for Approved Medicines, &#8805; Phase 2 Development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="gmab-20240502xex99d1006.jpg" alt="Graphic" style="display:inline-block;height:206.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:468pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;vertical-align:super;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;vertical-align:super;">*</sup><font style="vertical-align:super;">UltiMAb</font><sup style="font-size:6pt;vertical-align:super;"> </sup><font style="vertical-align:super;">transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol-Myers Squibb.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 14/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DARZALEX (daratumumab) &#8211; Redefining the treatment of multiple myeloma</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First-in-class human CD38 monoclonal antibody</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed and commercialized by Janssen under an exclusive worldwide license from Genmab </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Intravenous (IV) formulation approved in combination with other therapies and as monotherapy for certain multiple myeloma indications </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First and only SC CD38-directed antibody approved for the treatment of certain multiple myeloma indications, known as DARZALEX </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">FASPRO</i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the U.S., and DARZALEX SC in Europe</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">SC daratumumab is the first and only approved therapy for AL amyloidosis in the U.S., Europe, and Japan</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net sales of DARZALEX by Janssen were USD 2,692 million in the first three months of 2024</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Daratumumab is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis plasma cells. Genmab used technology licensed from Medarex to generate the CD38 antibody. Daratumumab is being developed and commercialized by Janssen under an exclusive worldwide license from Genmab. Under the terms of the agreement, Genmab receives royalties between 12% and 20% with Janssen reducing such royalty payments for Genmab&#8217;s share of Janssen&#8217;s royalty payments made to Halozyme; payments are further reduced in countries and territories where there are no patents. Daratumumab (marketed as DARZALEX for IV administration and as DARZALEX <i style="font-style:italic;">FASPRO </i>in the U.S. and as DARZALEX SC in Europe for SC administration) is approved in a large number of territories for the treatment of adult patients with certain multiple myeloma indications and is the only<i style="font-style:italic;"> </i>approved therapy in the U.S., Europe and Japan for the treatment of adult patients with AL amyloidosis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">European Summary of Product Characteristics</font><font style="color:#029c93;"> </font>for DARZALEX and DARZALEX SC and the U.S. Prescribing Information for <font style="color:#029c93;">DARZALEX</font> and <font style="color:#029c93;">DARZALEX </font><i style="color:#029c93;font-style:italic;">FASPRO</i><b style="color:#0070c0;font-size:13pt;font-weight:bold;"> </b>for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Kesimpta (ofatumumab) &#8211; Approved for the treatment of RMS</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Human CD20 monoclonal antibody developed and commercialized by Novartis under a license agreement with Genmab</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Approved in territories including the U.S., Europe and Japan for the treatment of RMS in adults</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First B-cell therapy that can be self-administered by patients at home using the Sensoready</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> autoinjector pen</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Ofatumumab is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody. Ofatumumab, marketed as Kesimpta, is approved in territories including the U.S., Europe, and Japan for the treatment of certain adult patients with RMS. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once monthly after starting therapy. Ofatumumab is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis. Under the terms of the agreement, Genmab receives a 10% royalty on net sales of Kesimpta, and Genmab pays a royalty to Medarex based on Kesimpta sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> and the <font style="color:#029c93;">European Summary of Product Characteristics</font> for the labeled indication and safety information for Kesimpta. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 15/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">TEPEZZA (teprotumumab-trbw) &#8211; First U.S. FDA-approved medicine for the treatment of TED</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed and commercialized by Amgen for the treatment of TED</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First and only U.S. FDA-approved medicine for the treatment of TED</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Also being explored in a clinical trial for the treatment of diffuse cutaneous systemic sclerosis (dcSSC)</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Teprotumumab-trbw, approved by the U.S. FDA under the trade name TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a validated target. Genmab used technology licensed from Medarex to generate the IGF-1R antibody. The antibody was created by Genmab under a collaboration with Roche. Development and commercialization of the product was subsequently conducted by Horizon under a sublicense from Roche. In October 2023, Amgen completed its acquisition of Horizon, including the rights to all commercialization and development of teprotumumab. Under the terms of Genmab&#8217;s agreement with Roche, Genmab receives a mid-single digit royalty on net sales (as defined) of TEPEZZA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> for the labeled indication and safety information for TEPEZZA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">RYBREVANT (amivantamab) &#8211; First regulatory approvals for a DuoBody-based medicine</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Part of Genmab and Janssen DuoBody research and license agreement</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First approved medicine created using Genmab&#8217;s proprietary DuoBody technology </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the agreement with Janssen, Genmab is eligible to receive milestones and receives royalties on net sales of RYBREVANT</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 4.5pt 11pt 0pt;">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of these, Janssen&#8217;s amivantamab, is a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and cMet, two validated cancer targets. The two antibody libraries used to produce amivantamab were both generated by Genmab. In collaboration with Janssen, the antibody pair used to create amivantamab was co-discovered. Janssen is responsible for the development and commercialization of amivantamab. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 4.5pt 11pt 0pt;">In 2021, Janssen received the first approvals in the U.S., Europe, and other markets for amivantamab, marketed as RYBREVANT, for the treatment of certain adult patients with NSCLC with EGFR exon 20 insertion mutations. These were the first regulatory approvals for a therapy that was created using Genmab&#8217;s proprietary DuoBody bispecific technology platform. Under our agreement with Janssen, Genmab is eligible to receive milestones and receives royalties between 8% and 10% on net sales of RYBREVANT subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions. Genmab pays a royalty to Medarex based on RYBREVANT net sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> and the<font style="color:#029c93;"> European Summary of Product Characteristics</font> for RYBREVANT for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">TECVAYLI (teclistamab) &#8211; Bispecific antibody approved for the treatment of relapsed and refractory multiple myeloma</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Part of Genmab and Janssen DuoBody research and license agreement</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Second approved medicine created using Genmab&#8217;s proprietary DuoBody technology </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 16/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the agreement with Janssen, Genmab is eligible to receive milestones and receives royalties on net sales of TECVAYLI</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of the products subsequently discovered and developed by Janssen is teclistamab, a bispecific antibody that targets CD3, which is expressed on T-cells and B-cell maturation antigen (BCMA), which is expressed in mature B lymphocytes. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In August 2022, Janssen received conditional marketing authorization from the European Commission for subcutaneously administered teclistamab, marketed as TECVAYLI, as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and a CD38 antibody and have demonstrated disease progression on the last therapy. In October 2022, Janssen received U.S. FDA approval of TECVAYLI (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug and a CD38 monoclonal antibody. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">TECVAYLI is the second therapy created using Genmab&#8217;s proprietary DuoBody bispecific technology platform to receive regulatory approval. Under our agreement with Janssen, Genmab is eligible to receive milestones and receives a mid-single digit royalty on net sales of TECVAYLI subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions.<br><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> and the <font style="color:#029c93;">European Summary of Product Characteristics </font>for TECVAYLI for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">TALVEY (talquetamab) &#8211; Bispecific antibody approved for the treatment of relapsed and refractory multiple myeloma</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Part of Genmab and Janssen DuoBody research and license agreement</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fourth approved medicine created using Genmab&#8217;s proprietary DuoBody technology </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the agreement with Janssen, Genmab will receive milestones and royalties on net sales of TALVEY</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of the products subsequently discovered and developed by Janssen is talquetamab, a bispecific antibody that targets CD3, which is expressed on T-cells and G protein-coupled receptor, family C, group 5, member D (GPRC5D), an orphan receptor expressed in malignant plasma cells. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In August 2023, Janssen received accelerated approval from the U.S. FDA for subcutaneously administered talquetamab-tgvs, marketed as TALVEY, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and a CD38 antibody. Subsequently Janssen received conditional marketing authorization from the EC for TALVEY for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and a CD38 antibody, and have demonstrated disease progression on the last therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 17/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">TALVEY is the fourth therapy created using Genmab&#8217;s proprietary DuoBody bispecific technology platform to receive regulatory approval. Under our agreement with Janssen, Genmab is eligible to receive milestones and receives a mid-single digit royalty on net sales of TALVEY subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions.<br><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <font style="color:#029c93;">U.S. Prescribing Information</font> and the <font style="color:#029c93;">European Summary of Product Characteristics </font>for TALVEY for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:12pt 0pt 3pt 0pt;"><b style="font-size:16pt;font-weight:bold;"><a name="_SIGNIFICANT_RISKS_AND"></a></b><b style="color:#029c93;font-weight:bold;">SIGNIFICANT RISKS AND UNCERTAINTIES</b><b style="font-size:16pt;font-weight:bold;"><a name="SIGNIFICANTRISKSANDUNCERTAINTIES_402181"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the industry and relate to operations, intellectual property, research and development, commercialization, and financial activities. For further information about risks and uncertainties which Genmab faces, refer to the 2023 Annual Report filed with NASDAQ Copenhagen and the Form 20-F filed with the U.S. SEC, both of which were filed in February 2024. At the date of this interim report, there have been no significant changes to Genmab&#8217;s overall risk profile since the publication of these reports. See Genmab&#8217;s Form 20-F for a detailed summary of risks related to our collaborations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 3pt 0pt;"><b style="font-size:16pt;font-weight:bold;"><a name="OLE_LINK15"></a><a name="OLE_LINK16"></a></b><b style="color:#029c93;font-weight:bold;">FINANCIAL REVIEW</b><b style="font-size:16pt;font-weight:bold;"><a name="FINANCIALREVIEW_601130"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="OLE_LINK6"></a><a name="OLE_LINK7"></a>The interim report is prepared on a consolidated basis for Genmab A/S (parent company) and its subsidiaries. The Genmab financial statements are published in Danish Kroner (DKK). The Genmab consolidated Group is referenced herein as &#8220;Genmab&#8221; or the &#8220;Company&#8221;.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s revenue was DKK 4,143 million for the first three months of 2024 compared to DKK 2,834 million for the first three months of 2023. The increase of DKK 1,309 million, or 46%, was primarily <a name="_Hlk117601415"></a>driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with Janssen and Novartis, respectively, EPKINLY net product sales and a milestone achieved under our collaboration with AbbVie.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:19.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:19.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.32%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,104</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,408</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 280</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 255</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 343</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 104</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 93</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 67</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net product sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 323</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.32%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,143</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,834</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Royalties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue amounted to DKK 3,104 million in the first three months of 2024 compared to DKK 2,408 million in the first three months of 2023. The increase of DKK 696 million, or 29%, was <a name="_Hlk117601480"></a>primarily driven by higher DARZALEX and Kesimpta royalties achieved under our daratumumab collaboration with Janssen and ofatumumab collaboration with Novartis. The table below summarizes Genmab&#8217;s royalty revenue by product.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 18/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:19.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:19.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.44%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:19.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,382</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,932</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 437</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 266</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 181</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 166</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 104</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 44</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total royalties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.44%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,104</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,408</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk164328790"></a>Net sales of DARZALEX by Janssen were USD 2,692 million in the first three months of 2024 compared to USD 2,264 million in the first three months of 2023. The increase of USD 428 million, or 19%, was driven by market share gains in all regions. Royalty revenue on net sales of DARZALEX<sup style="font-size:7.5pt;vertical-align:top;"> </sup>was DKK 2,382 million in the first three months of 2024 compared to DKK 1,932 million in the first three months of 2023, an increase of DKK 450 million. The percentage increase in royalties of 23% is higher than the percentage increase in the underlying net sales primarily due to a higher effective royalty rate and a decrease in Genmab&#8217;s effective rate of Halozyme royalty deductions in connection with the SC product net sales following the expiration of Halozyme&#8217;s patents in the EU in March 2024, partly offset by a lower average exchange rate between the USD and DKK and an increase in royalty reductions on net sales in countries and territories where there are no patent protections. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net sales of Kesimpta by Novartis were USD 637 million in the first three months of 2024 compared to USD 384 million in the first three months of 2023. The increase of USD 253 million, or 66%, was primarily driven by increased demand and strong access. Royalty revenue on net sales of Kesimpta was DKK 437 million in the first three months of 2024 compared to DKK 266 million in the first three months of 2023, an increase of DKK 171 million, or 64%. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue on estimated net sales of TEPEZZA was DKK 181 million in the first three months of 2024 compared to DKK 166 million in the first three months of 2023, an increase of DKK 15 million, or 9%.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other royalties consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY. These royalties were not material for the first three months of 2024 or 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk109307336"></a>Royalty revenue fluctuations from period to period are driven by the level of product net sales, foreign currency exchange rate movements and more specifically to DARZALEX, the contractual arrangement related to annual Currency Hedge Rate, Genmab&#8217;s share of Janssen&#8217;s royalty payments to Halozyme in connection with SC product net sales and the level of royalty deductions on net sales in countries and territories where there is no patent protection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reimbursement Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement revenue amounted to DKK 280 million in the first three months of 2024 compared to DKK 255 million in the first three months of 2023. The increase of DKK 25 million, or 10%, was <a name="_Hlk117601660"></a>primarily driven by higher activities under our collaboration agreements with BioNTech for acasunlimab and DuoBody-CD40x4-1BB.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Milestone Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk14190762"></a>Milestone revenue was DKK 343 million in the first three months of 2024 compared to DKK 104 million in the first three months of 2023, an increase of DKK 239 million primarily driven by an AbbVie milestone </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 19/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">achieved related to the U.S. FDA granting Priority Review for the sBLA for EPKINLY for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Milestone revenue may fluctuate significantly from period to period due to both the timing of achievements and the varying amount of each individual milestone under our license and collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaboration Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Collaboration revenue was DKK 93 million in the first three months of 2024 compared to DKK 67 million in the first three months of 2023, an increase of DKK 26 million, or 39%, primarily driven by an increase in net sales of TIVDAK. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Product Sales</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net product sales were DKK 323 million in the first three months of 2024. EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023. As EPKINLY is Genmab&#8217;s first commercialized product for which Genmab is recording net product sales, there were no net product sales recognized during the first three months of 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Financial Statement Note 2 in this interim report for further details about revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Cost of Product Sales</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab recognized cost of product sales of DKK 185 million in the first three months of 2024. <a name="_Hlk149042760"></a>Cost of product sales related to EPKINLY sales is primarily comprised of profit-sharing amounts payable to AbbVie of DKK 156 million as well as product costs. There were no cost of product sales recognized during the first three months of 2023, as EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of product sales accounted for 5% of total costs and operating expenses in the first three months of 2024.<b style="color:#029c93;font-weight:bold;"> </b>There were no cost of product sales recognized during the first three months of 2023, as EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Research and Development Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses amounted to DKK 2,300 million in the first three months of 2024 compared to DKK 1,741 million in the first three months of 2023. The increase of DKK 559 million, or 32%, <a name="_Hlk148641127"></a>was <a name="_Hlk117601788"></a>driven by the increased and accelerated advancement of epcoritamab under our collaboration with AbbVie, increased activities of DuoBody-CD40x4-1BB and acasunlimab under our collaboration with BioNTech and DuoBody-CD3xCD30, further progression of pipeline products, and the increase in team members to support the continued expansion of our product portfolio.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses accounted for 69% of total costs and operating expenses in the first three months of 2024 compared to 72% in the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Selling, General and Administrative Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses were DKK 857 million in the first three months of 2024 compared to DKK 676 million in the first three months of 2023. The increase of DKK 181 million, or 27%, was <a name="_Hlk117601923"></a>driven by the continued expansion of Genmab&#8217;s commercialization capabilities through the increase in team members to support EPKINLY in the U.S. and Japan post launch, and the investment in Genmab&#8217;s broader organizational capabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 20/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses accounted for 26% of total costs and operating expenses in the first three months of 2024 compared to 28% for the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Operating Profit </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Operating profit was DKK 801 million in the first three months of 2024 compared to DKK 417 million in the first three months of 2023.  </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Net Financial Items</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net financial items includes the following:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 295</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 192</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 43</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 85</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 590</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 284</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange rate loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (429)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (13)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (435)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 915</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (151)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Interest Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;">Interest income was DKK 295 million in the first three months of 2024 compared to DKK 192 million in the first three months of 2023. The increase of DKK 103 million was primarily driven by higher cash and cash equivalents and marketable securities, as well as higher interest rates on USD denominated marketable securities in 2024 versus 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Foreign Exchange Rate Gains and Losses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;">Foreign exchange rate gain, net was DKK 590 million in the first three months of 2024 compared to foreign exchange rate loss, net of DKK 429 million in the first three months of 2023. The USD strengthened against the DKK in the first three months of 2024, positively impacting our USD denominated securities and cash holdings. The USD weakened against the DKK in the first three months of 2023, negatively impacting our USD denominated securities and cash holdings.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">USD/DKK Foreign Exchange Rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;"> 6.8955</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.7447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.8492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.9722</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">% Increase/(decrease) from prior year-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.6%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">(1.8)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities Gains and Losses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gain on marketable securities, net was DKK 43 million in the first three months of 2024 compared to gain on marketable securities, net of DKK 85 million in the first three months of 2023. The decrease of DKK 42 </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 21/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">million was primarily driven by the change in interest rate outlooks for the U.S. and to a lesser extent for the EU.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Financial Statement Note 4 in this interim report for further details about the net financial items.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk100929385"></a><b style="color:#029c93;font-weight:bold;">Corporate Tax</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax expense for the first three months of 2024 was DKK 391 million compared to DKK 56 million for the first three months of 2023. The increase in corporate tax expense is primarily the result of Genmab&#8217;s higher net profit before tax and an increase in the estimated annual effective tax rate in the first three months of 2024 to 22.8% from 21.2% in the first three months of 2023. The increase in Genmab&#8217;s annual effective tax rate was driven by the impact of taxable differences which attributed to an increase in the current provision compared to 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Net Profit </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net profit for the first three months of 2024 was DKK 1,325 million compared to DKK 210 million in the first three months of 2023. The increase was driven by the items described above. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,914</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,268</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,670</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,867</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shareholders&#39; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32,497</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 31,610</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:28.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:28.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash Flow (DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:12.27%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,513</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,235</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,441)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13)</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (595)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (611)</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (523)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,611</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exchange Rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 326</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (216)</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk117601987"></a>Net cash provided by operating activities is primarily related to our operating profit, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. Cash provided by operating activities decreased in the first three months of 2024 compared to the first three months of 2023, primarily driven by significant AbbVie milestones achieved in 2022 with related cash received during the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) investing activities primarily reflects differences between the proceeds received from the sale and maturity of our investments and amounts invested, and the cash paid for investments in tangible assets. The increase in net cash (used in) investing activities is primarily driven by purchases of marketable securities exceeding sales and maturities to a greater extent during the first three months of 2024 compared to the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) financing activities is primarily related to the purchase of treasury shares, exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net settled </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 22/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted Stock Units (RSUs). The decrease in net cash (used in) financing activities between the periods is primarily driven by higher proceeds from the exercise of warrants of DKK 59 million in the first three months of 2024 compared to DKK 32 million in the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s USD denominated cash and cash equivalents, and marketable securities represented 90% of Genmab&#8217;s total cash and cash equivalents, and marketable securities as of March 31, 2024, and as of December 31, 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents included short-term marketable securities of DKK 897 as of March 31, 2024, compared to DKK 1,353 million as of December 31, 2023. In accordance with our accounting policy, securities purchased with a maturity of less than ninety days at the date of acquisition are classified as cash and cash equivalents. Refer to Financial Statement Note 3 in this interim report for further details about our marketable securities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Balance Sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of March 31, 2024, total assets were DKK 36,680 million compared to DKK 35,289 million on December 31, 2023. As of March 31, 2024, assets were mainly comprised of marketable securities of DKK 14,914 million, cash and cash equivalents of DKK 14,670 million and current receivables of DKK 4,679 million. The current receivables consist primarily of amounts related to royalties from our collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of March 31, 2024, total liabilities were DKK 4,183 million compared to DKK 3,679 million on December 31, 2023. The increase in total liabilities of DKK 504 million, or 14%, <a name="_Hlk117602057"></a>was <font style="background:#ffffff;">primarily driven by</font> <font style="background:#ffffff;">accruals related to the expansion of our product pipeline, and </font>an increase in lease liabilities for the commencement of a lease in the U.S. with respect to office and laboratory space.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shareholders&#8217; equity as of March 31, 2024, was DKK 32,497 million compared to DKK 31,610 million on December 31, 2023. The increase of DKK 887 million, or 3%, was primarily driven by Genmab&#8217;s net profit for the period and share-based compensation expenses, partly offset by the purchase of treasury shares. Genmab&#8217;s equity ratio was 89% as of March 31, 2024, compared to 90% as of December 31, 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:126.1pt;"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Team Members</b></font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of March 31, 2024, the total number of team members was 2,286 compared to 1,846 as of March 31, 2023. The increase was primarily driven by the expansion and acceleration of our pipeline, as well as the investment in the expansion of Genmab&#8217;s commercialization capabilities, including support for EPKINLY in the U.S. and Japan post launch activities, and broader organizational capabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:20.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Team Members</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.72%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development team members</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,601</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,293</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative team members</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 685</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 553</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total team members</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,286</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,846</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 23/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Legal Matters &#8211; Janssen Binding Arbitrations </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk117603397"></a><a name="_Hlk117601217"></a>In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters in favor of Janssen. Genmab did not seek a review of the award, and the award is final.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On June 9, 2022, Genmab announced the commencement of a second arbitration under the daratumumab license agreement with Janssen with claims for milestone payments for daratumumab SC of USD 405 million and a separate 13-year royalty term for daratumumab SC on a country-by-country basis, from the date of the first commercial sale of daratumumab SC in each such country. This second arbitration followed from the award in the prior arbitration, where the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share in Janssen&#8217;s royalty payments to Halozyme for its technology used in the daratumumab SC product. The tribunal based its ruling on the finding that DARZALEX <i style="font-style:italic;">FASPRO</i> constitutes a new licensed product under the license agreement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On April 21, 2023, the arbitral tribunal dismissed Genmab&#8217;s claims regarding the second arbitration, on the basis that these claims should have been brought in the first arbitration. One arbitrator dissented. Genmab filed a request for review of the award, which was denied on January 23, 2024.  As a result, the dismissal of Genmab&#8217;s claims in the second arbitration is now final.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 24/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="Statementsofcomprehensiveincome"></a><b style="color:#029c93;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</b><b style="color:#029c93;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,143</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,834</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cost of product sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (185)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,300)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,741)</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (857)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (676)</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total costs and operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (3,342)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,417)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Operating profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 801</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 417</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 928</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 284</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (13)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (435)</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net profit before tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,716</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 266</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Corporate tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (391)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (56)</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,325</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 210</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Basic net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 20.29</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3.21</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Diluted net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 20.18</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3.19</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Amounts which may be re-classified to the income statement:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Exchange differences on translation of foreign operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,373</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 229</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Toc16514648"></a><a name="_MON_1411968110"></a><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 25/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="FIRSTNINEMONTHSOF2019_377366"></a><a name="STATEMENTOFCOMPREHENSIVEINCOMEFORTHEFIRS"></a><b style="color:#029c93;font-weight:bold;">CONSOLIDATED BALANCE SHEET</b><a name="BALANCESHEET_757698"></a><b style="color:#029c93;font-weight:bold;">S</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 23</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 101</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 937</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 955</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 923</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 686</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 63</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 62</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 212</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 212</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 153</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 134</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,311</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,150</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 106</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 57</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,679</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,947</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,914</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,268</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,670</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,867</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 34,369</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 33,139</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 36,680</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 35,289</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SHAREHOLDERS&#8217; EQUITY AND LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 66</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,520</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,461</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 108</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 60</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Retained earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19,803</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19,023</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders&#39; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 32,497</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 31,610</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 918</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 680</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 480</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 480</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 26</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 35</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,424</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,195</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Corporate tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 122</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 54</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 92</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 90</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 33</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 33</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,512</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,307</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,759</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,484</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,183</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,679</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders&#39; equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 36,680</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 35,289</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Subsequent events to the balance sheet date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_MON_1411968448"></a><a name="_MON_1428926110"></a><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 26/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:17.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:38.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:38.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net profit before tax</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,716</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 266</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Financial items, net</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (915)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 151</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Adjustments for non-cash transactions</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 323</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 187</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 419</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,857</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities before financial items</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,543</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,461</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest received</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 301</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 179</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest elements of lease payments</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Corporate taxes paid</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (324)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (400)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by operating activities</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,513</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,235</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (28)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (104)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities bought</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4,533)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,874)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities sold</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,141</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,967</font></p></td></tr><tr><td style="vertical-align:middle;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments bought</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (21)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) investing activities</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,441)</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (13)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 59</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Principal elements of lease payments</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (24)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (21)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (545)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (543)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Payment of withholding taxes on behalf of employees on net settled RSUs</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (85)</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (79)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) financing activities</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (595)</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (611)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (523)</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,611</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash and cash equivalents at the beginning of the period</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,867</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 9,893</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 326</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (216)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14,670</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,288</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents include:</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Bank deposits</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 13,773</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,583</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Short-term marketable securities</p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 897</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 705</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.88%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14,670</b></p></td><td style="vertical-align:bottom;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,288</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 27/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b><b style="font-size:16pt;font-weight:bold;"><a name="STATEMENTOFCHANGESINEQUITY_43137"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retained</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shareholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">premium</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">earnings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 66</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,309</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 98</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14,809</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 27,282</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 210</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 210</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 19</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 210</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 229</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 32</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (564)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (564)</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Withholding taxes on behalf of employees on net settled RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (79)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (79)</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 66</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,341</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 117</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14,491</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 27,015</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 66</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,461</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 60</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 19,023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 31,610</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,325</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,325</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 48</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,325</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,373</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 59</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 59</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (628)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (628)</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 168</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 168</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Withholding taxes on behalf of employees on net settled RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (85)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (85)</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 66</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 12,520</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 108</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 19,803</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 32,497</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 28/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">NOTES TO THE FINANCIAL STATEMENTS</b><b style="font-size:16pt;font-weight:bold;"><a name="NOTESTOTHEFINANCIALSTATEMENTS_435403"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 1 &#8211; Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These interim statements of the Genmab Group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been audited by Genmab&#8217;s external auditors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2023 Annual Report (Annual Report). A number of amended standards became applicable for the current reporting period. There was no impact to Genmab&#8217;s financial statements as a result of adopting these amended standards. These interim financial statements should be read in conjunction with the Annual Report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_heading=h.1fob9te"></a><b style="font-weight:bold;">Management Judgements and Estimates under IFRS Accounting Standards</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In preparing interim reports, certain provisions under IFRS Accounting Standards (IFRS) require management to make judgements (various accounting estimates and assumptions), which may significantly impact Genmab&#8217;s financial statements. The interim report has been prepared using the same judgments and estimates as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Annual Report. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates, product sales or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reclassifications and Revisions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To facilitate comparison of information across periods, certain immaterial reclassifications and revisions have been made to prior period amounts to conform to the current period&#8217;s presentation. Refer to Note 1.4 in the Annual Report for further details.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 29/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_MON_1428393242"></a><a name="_MON_1428926213"></a><b style="color:#029c93;font-weight:bold;">Note 2 &#8211; Revenue </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below summarizes Genmab&#8217;s revenue by type and collaboration partner, and royalties by product, under Genmab&#8217;s agreements.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:42.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,104</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,408</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 280</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 255</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 343</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 104</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 93</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 67</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Net product sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 323</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,143</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,834</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,479</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,080</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 181</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 166</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 441</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 269</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 250</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 230</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 119</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 89</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 350</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,820</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,834</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Royalties by product:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,382</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,932</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 437</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 266</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 181</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 166</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 104</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 44</font></p></td></tr><tr><td style="vertical-align:bottom;width:53.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.96%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,104</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,408</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">* Excludes Genmab&#8217;s Net product sales</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">** Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Product Sales</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab recognized net product sales of DKK 323 million during the first three months of 2024. EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023. As EPKINLY is Genmab&#8217;s first commercialized product for which Genmab is recording net product sales, there were no net product sales recognized during the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deferred Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As part of the continued evaluation of deferred revenue related to the AbbVie Agreement, during the first three months of 2024, Genmab&#8217;s classification of deferred revenue reflects the current estimate of co-development activities as of March 31, 2024, with no deferred revenue recognized as revenue. These co-development activities are related to a performance obligation in connection with the product concepts under a research option agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 2.1 in the Annual Report for further details regarding revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 30/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk148453111"></a><b style="color:#029c93;font-weight:bold;">Note 3 &#8211; </b><a name="_Hlk148453130"></a><b style="color:#029c93;font-weight:bold;">Financial Instruments</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab&#8217;s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.04%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 81</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DKK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GBP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.76%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of March 31, 2024, 67% of Genmab&#8217;s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated compared to 72% as of December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below shows the fair value measurements by level for Genmab&#8217;s financial assets measured at fair value through profit or loss:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:25.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:25.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,914</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14,914</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13,268</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">13,268</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 38</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.34%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 153</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">87</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">134</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#8217;s marketable securities (Level 1). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab&#8217;s marketable securities and other investments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 31/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 4 </b><a name="_Hlk148453252"></a><b style="color:#029c93;font-weight:bold;">&#8211; Financial Income and Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 295</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 192</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Gain on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 43</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 85</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Gain on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 590</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 284</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6)</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Foreign exchange rate loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (429)</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (13)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (435)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:59.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 915</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (151)</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Interest Income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;">Interest income was DKK 295 million in the first three months of 2024 compared to DKK 192 million in the first three months of 2023. The increase of DKK 103 million was driven by higher cash and cash equivalents and marketable securities, as well as higher interest rates on USD denominated marketable securities in the first three months of 2024 compared to the first three months of 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Foreign Exchange Rate Gains and Losses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;">Foreign exchange rate gain, net was DKK 590 million in the first three months of 2024 compared to foreign exchange rate loss, net of DKK 429 million in the first three months of 2023. The USD strengthened against the DKK in the first three months of 2024, positively impacting our USD denominated securities and cash holdings. The USD weakened against the DKK in the first three months of 2023, negatively impacting our USD denominated securities and cash holdings.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:13.32%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">USD/DKK Foreign Exchange Rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.32%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 6.8955</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.7447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.8492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.9722</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.32%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">% Increase/(decrease) from prior year-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:13.32%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.8)%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;margin:0pt 0pt 11pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities Gains and Losses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gain on marketable securities, net was DKK 43 million in the first three months of 2024 compared DKK 85 million in the first three months of 2023. The decrease of DKK 42 million was primarily driven by the change in interest rate outlooks for the U.S. and to a lesser extent for EU.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 32/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 5 &#8211; Share-Based Payments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Unit Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has established an RSU program (equity-settled share-based payment transactions)<font style="letter-spacing:-0.2pt;"> </font>as an incentive for Genmab&#8217;s employees, members of the Executive Management, and members of the Board of Directors. RSUs granted to Executive Management are performance-based.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:8.5pt;">RSUs granted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 436,774</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 273,236</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average fair value per RSU granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 2,015.91</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 2,639.29</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:8.5pt;">RSUs vested</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 117,107</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 73,128</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Refer to Note 4.6 in the Annual Report for details on the RSU program.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warrant Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has established a warrant program (equity-settled share-based payment transactions) as an incentive for all Genmab employees. Following Genmab&#8217;s Annual General Meeting on March 29, 2023, members of the registered Executive Management and members of the Board of Directors may only be granted RSUs.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:8.5pt;">Warrants granted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 329,027</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 185,747</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 2,014.28</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 2,655.65</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average Black-Scholes fair value per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 653.05</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 940.56</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:8.5pt;">Warrants exercised</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 48,429</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:8.5pt;white-space:pre-wrap;"> 24,359</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price on date of grant per warrant exercised (DKK)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 1,211.78</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;white-space:pre-wrap;"> 1,306.89</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">% change in share capital - warrants exercised</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.07%</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.04%</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.6 in the Annual Report for details on the warrant program.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share-Based Compensation Expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Share-based compensation expenses related to Genmab&#8217;s RSU and warrant programs for the first three months of 2024 were DKK 168 million compared to DKK 115 million for the first three months of 2023. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share Repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, Genmab&#8217;s 2021 and 2023 authorizations have shares available for repurchase, whereas Genmab&#8217;s 2019 authorization has expired. In addition, at Genmab&#8217;s Annual General Meeting on March 13, 2024, a new authorization to acquire treasury shares up to a nominal amount of DKK 3,500,000 was granted.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 33/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.45%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:14.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.39%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024 </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Authorization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023 </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Authorization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.85%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;padding-left:6.2pt;text-align:center;text-indent:-6.2pt;margin:0pt;"><b style="font-weight:bold;">2021 </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Authorization</b></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Number of shares authorized for repurchase<sup style="font-size:6.75pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,500,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 500,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 500,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Actual shares repurchased under authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 121,123</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 450,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Shares available for repurchase as of March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,378,877</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 500,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 50,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:73.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><sup style="font-size:6pt;vertical-align:top;">1</sup> Nominal value of DKK 3,500,000 for 2024, and DKK 500,000 for 2023 and 2021 Authorizations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced on February 14, 2024, and March 15, 2024, Genmab initiated two share buy-back programs. The purpose of the share buy-back program announced on February 14, 2024, was to honor our commitments under the RSU program. The share buy-back program announced on March 15, 2024 is in support of our capital allocation strategy. During the first three months of 2024, Genmab acquired 311,123 of its own shares <font style="background:#ffffff;">under both programs</font>, representing approximately 0.5% of share capital as of December 31, 2023. The total amount incurred to acquire the shares, including directly attributable costs, was DKK 628 million and was recognized as a deduction to shareholders&#8217; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of March 31, 2024. During the first three months of 2023, Genmab acquired 220,000 of its own shares, representing approximately 0.3% of share capital as of December 31, 2022. The total amount incurred to acquire the shares, including directly attributable costs, was DKK 564 million and was recognized as a deduction to shareholders&#8217; equity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of March 31, 2024, 981,465 treasury shares were held by Genmab. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk117758412"></a><a name="_Hlk139986517"></a><a name="_Hlk148676828"></a><b style="color:#029c93;font-weight:bold;">Note 6 &#8211; Related Parties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s related parties are its Board of Directors, Executive Management, and close members of the family of these persons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the Executive Management.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other than the remuneration and other transactions relating to the Board of Directors and the Executive Management described in Note&#160;5.1 in the Annual Report, there were no material related party transactions during the first three months of 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a name="_Hlk117757759"></a><b style="font-weight:bold;">Changes to the Executive Management and the Board of Directors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There were no changes to the Executive Management team during the first three months of 2024. The Executive Management team is comprised of: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Jan van de Winkel, President and Chief Executive Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Anthony Pagano, Executive Vice President and Chief Financial Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Judith Klimovsky, Executive Vice President and Chief Development Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Anthony Mancini, Executive Vice President and Chief Operating Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Birgitte Stephensen, Executive Vice President and Chief Legal Officer, </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Christopher Cozic, Executive Vice President and Chief People Officer, and, </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 34/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Martine van Vugt, Executive Vice President and Chief Strategy Officer.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Jan van de Winkel, President and Chief Executive Officer, and Anthony Pagano, Executive Vice President and Chief Financial Officer, are formally registered as executive managers with the Danish Business Authority.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Following Genmab&#8217;s Annual General Meeting on March 13, 2024, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Elizabeth O&#8217;Farrell, Paolo Paoletti and Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period. Mijke Zachariasse, Martin Schultz and Takahiro Hamatani continue to serve as employee-elected board members for a three-year period expiring in 2025. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 7 &#8211; Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the balance sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 923</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 686</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 923</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 686</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 92</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 90</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 918</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 680</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:57.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,010</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 770</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first three months of 2024, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of a lease in the U.S. with respect to office and laboratory space. During the first three months of 2023, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of a lease for the new headquarters in Denmark. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Leases not yet commenced</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first three months of 2024, Genmab entered into a lease agreement with respect to office space in Japan with a commencement date in June 2024 and a non-cancellable term through June 2029. The total future minimum payments over the term of the lease and estimated capital expenditures to fit out the space are not material.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 35/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the statements of comprehensive income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:37.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 22</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 21</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 22</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 21</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Variable lease payments, short-term lease expense, lease interest expense and low-value leases are not material.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 8 &#8211; Subsequent Events to the Balance Sheet Date</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">On April 3, 2024, Genmab and ProfoundBio announced that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. The acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio&#8217;s novel ADC technology platforms. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio&#8217;s closing net debt and transaction expenses). The proposed transaction is expected to close in the first half of 2024. The closing of the proposed transaction is subject to the satisfaction of customary closing conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">No other events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of March 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 36/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">ABOUT GENMAB</b><b style="font-size:16pt;font-weight:bold;"><a name="ABOUTGENMAB_556806"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;text-indent:0pt;margin:12pt 0pt 3pt 0pt;"><i style="font-style:italic;font-weight:normal;">Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab&#8217;s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;font-weight:normal;">) antibody medicines.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;"> </i><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit </i><i style="color:#029c93;font-style:italic;">Genmab.com</i><i style="font-style:italic;"> and follow us on </i><i style="color:#029c93;font-style:italic;">LinkedIn</i><i style="font-style:italic;"> and </i><i style="color:#029c93;font-style:italic;">X</i><i style="font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">This Interim Report contains forward looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on </i><i style="color:#029c93;font-style:italic;">www.genmab.com</i><i style="font-style:italic;"> and the risk factors included in Genmab&#8217;s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at </i><i style="color:#029c93;font-style:italic;">www.sec.gov</i><i style="font-style:italic;">. Genmab does not undertake any obligation to update or revise forward looking statements in this Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; Genmab in combination with the </i><i style="font-style:italic;">Y-shaped Genmab logo</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; HuMax</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; DuoBody</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; HexaBody</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; DuoHexaBody</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; HexElect</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174; </sup><i style="font-style:italic;">and KYSO</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">; Tivdak</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> is a trademark of Seagen Inc.;</i> <i style="font-style:italic;">EPCORE&#8482;, EPKINLY</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">, TEPKINLY</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> and their designs are trademarks of AbbVie Biotechnology Ltd.; Kesimpta</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> and Sensoready</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> are trademarks of Novartis AG or its affiliates; DARZALEX</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">, DARZALEX FASPRO</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">, RYBREVANT</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;">, TECVAYLI</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> and TALVEY</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> </i><sup style="font-size:6pt;font-style:italic;vertical-align:top;"> </sup><i style="font-style:italic;">are trademarks of Johnson &amp; Johnson; TEPEZZA</i><sup style="font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-style:italic;"> is a trademark of Horizon Therapeutics Ireland DAC. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 37/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20240502xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Quarter of 2024</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:16pt;font-weight:bold;"><a name="_Toc16514654"></a></b><b style="color:#029c93;font-weight:bold;">DIRECTORS&#8217; AND MANAGEMENT&#8217;S STATEMENT ON THE INTERIM REPORT</b><b style="font-size:16pt;font-weight:bold;"><a name="DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"></a></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">The Board of Directors and the registered members of Executive Management have today considered and adopted the unaudited interim report of the Genmab Group for the quarter ended March 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">The interim report is prepared in accordance with IAS 34, &#8220;Interim Financial Reporting,&#8221; as issued by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish disclosure requirements for interim reports of listed companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">We consider the applied accounting policies to be appropriate and, in our opinion, the interim report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the Group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Furthermore, we consider the Management&#8217;s Review to give a true and fair account of the development in the Group&#8217;s activities and financial affairs, results of operations and the Group&#8217;s financial position as a whole as well as a description of the significant risks and uncertainties which the Group faces, as further described in our 2023 Annual Report and the Form 20-F filed with the U.S. Securities and Exchange Commission in February 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Copenhagen, May 2, 2024</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-style:normal;font-weight:bold;">Registered Members of Executive Management</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1.25pt;"><td style="vertical-align:bottom;width:27.38%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:27.38%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.7pt;"><td colspan="2" style="position:relative;vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:0pt;position:relative;width:100%;"><div style="height:3pt;left:31.41%;max-width:68.59%;position:absolute;top:419pt;width:108pt;z-index:251660288;"><div style="height:0.5pt;left:0pt;padding-bottom:2.5pt;position:relative;width:106.5pt;"><img src="gmab-20240502xex99d1007.jpg" alt="Graphic" style="height:0.5pt;width:106.5pt;"></div></div></div><div style="height:0pt;position:relative;width:100%;"><div style="height:3pt;left:30.53%;max-width:69.47%;position:absolute;top:417.15pt;width:108pt;z-index:251658240;"><div style="height:0.5pt;left:0pt;padding-bottom:2.5pt;position:relative;width:106.5pt;"><img src="gmab-20240502xex99d1007.jpg" alt="Graphic" style="height:0.5pt;width:106.5pt;"></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1009.jpg" alt="Graphic" style="display:inline-block;height:34.54pt;width:69.19pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1010.jpg" alt="Graphic" style="display:inline-block;height:32.66pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:85.47pt;"></p></td></tr><tr style="height:14.7pt;"><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Jan van de Winkel</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anthony Pagano</p></td></tr><tr style="height:13.95pt;"><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(President &amp; CEO) </p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CFO)</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;padding-left:28.8pt;text-indent:-28.8pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-style:normal;font-weight:bold;">Board of Directors</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:3.4pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr style="height:27.4pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1011.jpg" alt="Graphic" style="display:inline-block;height:30pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:44.4pt;"></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1012.jpg" alt="Graphic" style="display:inline-block;height:20pt;width:69pt;"></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1013.jpg" alt="Graphic" style="display:inline-block;height:21pt;width:102pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deirdre P. Connelly</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pernille Erenbjerg </p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anders Gersel Pedersen</p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Chair)<font style="white-space:pre-wrap;">  </font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Deputy Chair) </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1014.jpg" alt="Graphic" style="display:inline-block;height:30pt;width:104pt;"></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1015.jpg" alt="Graphic" style="display:inline-block;height:28pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:58pt;"></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1016.jpg" alt="Graphic" style="display:inline-block;height:35.11pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:128.82pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rolf Hoffmann</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paolo Paoletti</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Elizabeth O&#8217;Farrell</p></td></tr><tr style="height:16.15pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1017.jpg" alt="Graphic" style="display:inline-block;height:26.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:57.25pt;"></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1018.jpg" alt="Graphic" style="display:inline-block;height:20.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:108.18pt;"></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20240502xex99d1019.jpg" alt="Graphic" style="display:inline-block;height:27pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:32.92pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Mijke Zachariasse</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Takahiro Hamatani</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Martin Schultz</p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected) </p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected) </p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 33</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 38/38</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmab-20240502xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TC]J']ICX
MB:=\8-=T#1]:NO#>EZ1,L$,%F%1Y?D5C([$9;=G('3&..I/K7[''[4.M_%#5
MKKPAXMD2\U6&V-U9ZDD81ID4@.DBJ -PW A@!D9SR,GT;X[?LI>%OCE>1ZI<
M3SZ'X@C01'4;-5;SD'194/#8['(/;.,"N>^&O[*UI^S_ *%XHUW0=0N?$/C.
M32YX;&XGA6-(FV[E5(P3R65<DD] ..<^[.OA)X7DY;32[=?4_/J&7YU1SAUG
M4YJ+;;N]+=N7NNED?1>X9QD9ZXI:_(Y?%&MC5SJQUC4EU?S/,:]-U()_,SR2
MV<YSVK]$_P!EKXF:I\4OA1;ZCK1\W4[.YDL)KD*%^T; I$F!QDA@#CN#7A'Z
M">O4@8'."#C@XKY/_;=^+NO^%I]'\):+=SZ7!?VSW=Y=VSE))4W;%B5ARHX)
M;')RHZ9S\[_L\ZYXCL?C+X7CT*[NS<7=]''<PK(S)- 3F7S!T(";CD]" >M
M'IO[0/[5_BN]\::KH7A347T'1M-N'M3<6RKY]S(A*NQ<@[5W @ 8X&2><#T;
M]C+XT>*_B#?:]H7B.\DUB*QMX[F"_F4"5-S%3&S #=GJ">>#U[:GQ%_8C\/^
M-O%]]KMCKUYH0OY6N+FTC@29#(QRS(205R<G!R,DX]*];^$_P@\/?!SP^^EZ
M%#(6F8275Y<,&FN7 P"Q  P!P   /Q.0#MZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /)O&W[+GPY\>ZU)JVH:(UO?S/OGEL+A[<
M3-W+JIP2>YQD^M> ?M&_%W4/@[K%E\-_ATR^%=)TNV2:XDM$!EDDDRP7<V3C
M&&)ZL6Y/'/VQ7R5^U?\ LU>)/'/C&+Q9X3M4U.2X@2"]LC,L<BLG"R+N(!!7
M (SD;0><G !<^"ESI7[6WP_N=/\ B'8)J>M>'KA8TU* F"9HY%RK93&"=C!A
MT.T'&:]M^&WP/\&?"<RR>'=(6WO)EV27L[M-.R_W=[$D#V&!7&_LJ_!+4/@Y
MX/OSK;1C7-6F6:X@A<.L"("$CW#@GEB2./FP,XR?;J "BO.?CA\<] ^!7A==
M5U@M<W=P3'9:="P$MRX&3@G[JC(W,>!D=20#X;I?CW]IWXFVJ:SH7A[1/"^D
M3C?;17ZJ))$/(/[PECD=]J@]JZZ>&G4CSMI+NW8\?$YI0P]7V"C*<]VHJ[2\
M^B^;/KBBOFSX<?&WXLZ5\0M)\&_$GP"V_4W9+?6='7,(VC<S.=S(5 Y.&4C^
MZ:^DZRJTI4G:5M>SN=6$QE/&0<J::L[----/T84445B=P4444 %%%% !1110
M 4444 %%%% !17D/[6=WJ.F_ +Q1J&DZG>:1?V:0S1W-C.T4F/.0,NY2#@JQ
M%2?LHZQ>:]^SYX-O;^YEN[M[>5'GG<N[[9Y%!+'DG"CK71[%^Q]M?K;\+GF_
M75]>^I<NO)SW^=K'K5%%%<YZ04444 %?$O[97QJ\2V?Q#_X1'1M5N]&T[3[>
M*6<V4S1/<2R#<-S*0=JKMP,]22<\8^VJ^9/VGOV6]5^*/B2W\3^%Y[1=2:%;
M:\M+QS&LH7.R16 /(!P01R .>.0#3_8R^+&M?$7P=J^G:_=2:C?:+/&B7LQS
M)+#(I*AS_$RE&&3R1C/K7T17D?[-OP/?X)>#[JVO;J*\UO4IA/>2P9\I,#"1
MIGDA1GD@9+'BO7* /AC7E'QT_;P@TC41]IT/PZYC%M(-R;;=-[ CH0TY /J,
M"ON>OASX#D67[>'CV&XXEEDU/R]W?,R./_':^J?C+H/C3Q%X--MX!UV#P]X@
M6XCD6ZN5#1M&,AT.4?&0<].H%>MC5>=.G>R45Z>I\;D<W&AB<4XN4W4E=+=V
MV2OVZ'=5A>./&VD?#KPKJ/B+7+G[+IEC'YDC@99CG"JH[LQ( '<D5\4_%GQ9
M^T!\#;[PU_PD?Q M+V'5[HQ1KI\$38",F[=N@7&0XZ>]=I_P4=UJYMO!/A'2
M8Y"EO>7\T\H!X8Q1@+G\9"?PJ88%NI3BY)J5]5Y;FM;/U'"XFK&E*,Z26DK;
MRVV;+FD?'+X]?%RTDU_P!X&TBP\,;V%J^K2@RW(4D'!,B \@C(&,Y&XXKN/@
M'^TS<?$;Q-J'@GQAHG_"+>.; ,SV8)\J<+C=L#<JP!!VY.5.X$C..&\&?MD:
M#X3\(:)HMM\._&'V?3[*&U0Q6"[2$0+D?-SG&<^]>:O\0)?B3^V#X'\8Z+X7
MUW1+9Y;:RNC?V;(Q)\R-F)7(V['49)[5V/#\ZG&5-123L^NG?76YXT<R^KRH
MU:6*=64I)3BUI9[M:*UNFI]!_M0?M ZY\"+OPDUAIMA=Z;JMPT=U/=%R\2HT
M98*%('*,V"<X(Z&N4U3]I3XH?$:>XG^$7P\.I>'8&94UK6%*+=X/)B5GC&/Q
M8^H!XK"_X*)HLFF_#Q& 96U&<$'H1MCXKZ^M;6&QMHK>VACM[>) D<42A410
M,  #@ #L*Y+TJ5"G4<$Y.^^VC/72Q>,S#$X=5W"G#DV2OK'HVG9=]+^9X-^S
M=^TQ=_%W6-8\+>)]%7P_XPTE6>:WCW!)%5@C_*WS(RL0"I)Z@@]<+^U%^T%K
MOP'O/"+Z?IVGW>F:K.Z7<UUO,D:QM&6"!2!DHQP3G!'2O+_A, O[?WCX 8_T
M:Y/'TMZM_P#!0Y%EMOALCJ'1M2G5E(R""(LBMU0I?6X1Y?=DKV^1Y\L?BUDU
M>I[3]Y3DXJ75VDEK\F:.N?M,?%?Q]Y^H?"CX=27GAB!FV:KJ<)+W@4G)B3>G
M!]!N/T/%,\,_MZV6I>!_]*\-7-U\06NOL4'A[3U<K<N1Q(I()5<Y!7YF!&!G
MJ/J^VMH;.WBM[>)(((E"1Q1J%5% P  .  .U?%_[%>EV=S\=OBQ>S6L,MW:7
M,BV\[H"\(>YF#[3VR% ./2HINA5I3DZ=E&UM=7ZLZ,3',,+BZ%.&);=7F3NE
M965[Q73RNWYEKQ#^U+\:OA9?:?K'C[X?V-CX7O9A'Y=OD2IWVB02L ^T$A74
M9P>G;ZS3Q39W'A%?$=HL]_I\ED+^);6,O+-&4WJ$3J6(Q@>IKP;]OT _ )LC
MIJMKC_Q^O4?@&ZI\#/ ;NP55T.T)9C@ >2M8UE"="%912=VM#LP,L10S"M@I
MU7.*BI)RM=-NSV2T/$+/]I7XN_%MWG^&'PTCCT3)$>J:Z^U9,=QET7/LI?%2
M^#?VH/'GA+XI:5X'^+GABSTB7572.TU'3R0FYVVH3\[JZEL*2""I/(KJ-:_;
M#\-QZW-H'@7PYK7Q!O[;Y7&@VV;=,<</W'N%V^A-?/7[0?Q%U[XC?%3X7'7/
M NI>!YK74$6%-1D#M<AKB#)7"C&W:,_[U=M*BJKY)4E&+3Z^]MZW_ \/%XUX
M6"KTL9*I44DFK>X[M)K2-E_X%?YGU3^UO_R;GXX_Z]$_]'1U\Z_!+X^^-K7X
M1^'/!OPP\$2^)M6TR&7^T=1NU(M;=WFD=4'S*"=K Y+#V!KZ*_:W_P"3<_''
M_7HG_HZ.JG[&UM#;_LW^#VBB2,RI<22%% +M]HD&X^IP ,^PKFI3C#!WE&_O
M?H>IBZ-7$9TH4JCA^ZU:2O;GV5]O6S/,O"'[8'BSPGXZLO"_QA\)1^&3>L%B
MU*W1HT3)P&8,S*R9X+JWR]Q7UKUKY=_X*&:):WOP;TO49(U-W9:M&D4N.0DD
M;AU^API_X"*[CX6_%:ZG^&7A&2XB\^X?1[-I)6R2[&%,D_4U%:E&K2C6IQM>
MZ:Z&^"Q57"8NK@<54<U%*49/>SZ.V^O4]KHHHKRSZP**** "BBB@#XH_:3T/
M4_@-^T1H/QCTVRDN]"NY4345A'W)-GE2(3T'F1\J3QN!]J^J? OQ:\(_$C2H
MK_P_KUE?1NH9HA*%FB/]UXS\RD>XKHM7TBQU_3+G3M2M(;^PN4,<UM<1AXY%
M/9E/!KYR\7?L'_#"_NGO;-=8T7>W^HL+Q3&OT$B.1],UZL)4\7&-.I=2BK76
MNGF?'UZ>(R:K4Q&&Y94ZCNXMM-2>[32>CZW1P?[?OB'2]3UCX<65GJ5I=7EK
M>SO/;P3*[Q*S0!2P!RN<'&?0UW/[?GP^N_%GPDM-:L8FGET"Z-Q.B#)%NZ[)
M&Q_LG83[ GM72> ?V+?A?X(O8-0&E7&N7D962-]8G\Y48<@^6H5"?JIKW66)
M)XGBE19(W4JR.,A@>H([BJGB(T)4HT[ODOOUN9T,NJYA3Q53$VC[=1LE=VY5
M9/5*^MF>6?L^_&;P]\4/AUHDMIJ5NNK6UI%!?6$DH$T,JJ%8E2<E21D-T(/K
MD#K_ /A9OA0^,;;PHNOV,GB*YC>6/3XY0\A5!ELXX!QS@X) ) X->.>+_P!A
M;X7^(=4?4+>WU+06D;+0:5=*D()Z[5='V_1<#VKN/A3^S1X!^#ER;W0=),NJ
MD%?[2OY//N #U"DX"9[[0,]ZRJTZ'*ZL6]=E9?G?]#JP>*S!U(X2I&%XVYI7
M>J7966K];'A__!1'_CP^'7_82G_]!CK["K@?BO\ !'PQ\9XM)C\2Q74BZ9*T
MUO\ 9K@Q89@,YQU^Z*[ZL:M12H4X+=7_ !9WX7#3I8_%5VU:?);OHFG<^,OA
M/_R?]X^_Z]KC^5O5W_@H5_JOAI_V$YOY15[_ *'\"_"WA[XHZI\0+.*[7Q%J
M*.D[O<%HB&V9PG0?<6G_ !5^"7ACXRKHX\2174@TJ9I[;[-<&+#-MSG'7[HK
ML6(A]8IU+:))?@>'/+:SRS$X>ZO.;:WM9R3UT.^KXT_8D_Y+1\8O^OH_^E4]
M?9=>??#KX&^%OA;XAU_6M"BNH[[6W\R\,]P9%)WL_P H/3EVKCHU%"E4B^MO
MS/;QN&G6QF%JQ:M!R;^<;:'E_P"WY_R0%_\ L*VO_L]5O&5WJ-C^P1;RZ8SK
M<?\ ",V*.T9.X0L(EE_\AE\^V:]L^*'PMT+XO^%SH'B*.>33C.EQMMIC$V]<
MXY';DUJ:'X0TO0/"%EX8@M_.T:ULUL%@N?WF^$)LVOG[V5X.>M:PKQA1@K7M
M*YRULOJ5L;7FI64Z?*NZ>NIX=^P<FB)\![4Z;Y']I->3_P!I[,>8)=Y";^_^
MKV8]OQKR']K3X@>'_$'[1GPUL;+4H+H:'>0#4)8G#1P,]S&VTMTR%3)],C/.
M0/4M6_88^'?]N-/IU[XAT."Z8[[33M0"Q!<_=&Y&;;[%C71>)_V0OAK>_#JV
M\,PZ3+IUM:7*W27MI+B[>0X5R\C!MVX<$$8'&,8%=ZE2AB/;MM\U^VE_F?.3
MIXRMEW]GQC%>Q2N[O7E:>BY5:]M7KZ&M^UTP3]G+QN3_ ,^L8_.:,5Q_[%OQ
M2\+:A\&-!\-)K-K#KNEB6*YL+B01R_-,[AE!^\I##D9]#BO8O&7POT+QQX!?
MP;J$=Q'H+1PPF&VG9'V1E2B[^3C*+]<5YOXI_8Q^&'B7P]I>FOI=S82:7;_9
MX+^RGV7+("3B1B"'.2>6!/I@5QT94IT/8SOK*]UZ'NXRGBZ6/^O45%J-.S3;
MU]Z^C2_3Y'DO[=GQ*L/&-KX<^''AFYBUK6[G4DGG@LG$FQ]I2*(D<;F:0G'4
M!><9%?3W@CX<:?X7\%Z!HTT*33:=I]O:/(.CM'&J$_B17&?!_P#96\ _"#4%
MU?2;*YO]7"D1WVIRB62$$8/E@*JJ2.,@9QQG!KV2HQ-6,8QH4[VCU[MFV686
4I5JU,PQ5N:I9)+5**\W:[?4__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gmab-20240502xex99d1005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (L Z@# 2(  A$! Q$!_\0
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MH7LODV=K$TTTFTMM11DG !)X':K=8/CW2+CQ!X*US3+0*;J\LIH(@[;5W,A
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M*S149QEI%W)Z**BN+F*TB:6:1(HE&6>1@J@>Y-(INQ+163_PE6C_ /06L?\
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M+V/_ (%1_P"-'_"5:/\ ]!:Q_P# F/\ QI6?8/:T_P"9?>:U%9/_  E6C_\
M06L?_ F/_&C_ (2K1_\ H+6/_@3'_C19]@]K3_F7WFM163_PE6C_ /07L?\
MP*C_ ,:/^$JT;_H+V'_@5'_C3Y7V#VM/^9?>:U%9/_"5:-_T%[#_ ,"H_P#&
MC_A*M&_Z"]A_X%1_XT<K[![6G_,OO-:BLG_A*M&_Z"]A_P"!4?\ C1_PE6C?
M]!>P_P# J/\ QHY7V#VM/^9?>:U%9/\ PE6C?]!>P_\  J/_ !H_X2K1O^@O
M8?\ @5'_ (T<K[![6G_,OO-:BLG_ (2K1O\ H+V'_@5'_C1_PE6C?]!>P_\
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MTIG.WCJ3GGW#ZIA_^?<?N1]$?\*9\ _]"1X=_P#!7!_\30/@SX /_,D>'?\
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M<'_Q-=AN%*6%'//N'U3#_P#/N/W(X[_A3'@'_H2/#O\ X*X/_B:/^%,> ?\
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M ,%<'_Q-=@&&:"PHYY]P^J8?_GW'[D<?_P *8\ _]"1X=_\ !7!_\30WP8\
MX/\ Q1'AT?\ <+@_^)KL-P]:"PQ1SS[B^J8?_GW'[D?@AXLUF_MO%&KPQ7MQ
M%%'>3*J)(0% <X '85D?\)!J?_00NO\ OZU6O&?_ "-VM_\ 7]-_Z&:QJ]E-
M]S\DG3@IOW5]Q?\ [?U/_H(77_?UJ/[?U/\ Z"%U_P!_6JA13N^Y'LX?RK[B
M_P#V_J?_ $$+K_OZU']OZG_T$+K_ +^M5"BC7N'LX?RHO_V_J?\ T$+K_O\
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M:Q=^YSYDE&I"W\L?R.>_X5QX4_Z%C1O_  7P_P#Q-'_"N/"G_0L:-_X+X?\
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MV_/.[.:QOA'^SGX(^#?AT:9H^CVEQ</#+;W6JW=K"UY>122O(8YI @+J#(0
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M*C=@9QP.@& .OH **** ,/QK>IIGA+5[R2ZN;*.WMI)FN+-5::,*,DH&^4G
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M3P_#;:7</\5K8P:@5%G*^H606\*L=PC.,/G.T[?0=#7 G]F[Q%I.B:F-)O\
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MPO 4DNP)^88([<BLW_A.;K3M4\/:=K<GC/P_>:W>?8+*._AT]_,=822S&%Y
MJ]\GG=CC%:/Q'^!:^+?@2/AWILMM;PB*WA+W:LT;JCJS[@.26PWXM65\0/@'
M<6LO@JZ^&^F^']'?P]JCZBUA>>9;V\Y:/8?FB5B#[X-',P]A#S^]_P"9Z,/"
M&IG'_%6:MT_N0?W-O_//U^;Z^W%//A+4R"/^$JU4$@C.R#CY-N?]7Z_-]?;B
MMCP\VJOHUJ=;ALX-4*?OX["5Y8%;_89U5B/J!6C1S,/80\_O?^9RC>$-396
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MP@%1[,<Y.#570O\ D*1_0_RKJATKSZ[:F?=Y+!/"Z]V<^WAJ_)<CQ'J*[BY
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MH UZ*R#HET0X_MF^&0P!'E\9C"C'R]B-X]R>W%$^BW4HD"ZS?1;M^"GE_+E
MHQE>Q!8>Y.<CB@#7HK(DT6Z<28UB^3?OQCR_EW  8^7^'!(]V.<\47.C74_F
M;-8OH-V_'E^7\N[&,97^'!Q_O'.>, '2Z%_R%(_H?Y5U5>?Z1HMU+J)"ZU?1
MEQ)@IY?R[L$8^7^'! _WCG/%=+/H%Y,'VZ[J$6[?C9Y?R[G##&4_A VCV)SD
M\UY]=>\?>9+)K"Z+JS;HK%;0;MBQ_MW4%R6.!Y?&7##'R=@-@]B>_-))H%X[
M9&O:@G)X7R^\F_\ N=A\G^[[\US:=SWN:7\IMU;TH_\ $Q@_WJYI=!NPP/\
M;NH'!Z'R^?WF_P#N>GR?[OOS5G2_#UXVI6Q&O:BN&7('E<X<O_<[@[#_ +(]
M>:B:7*]3IPLI>WA[O5?F>EBBN>A\,WT1C+>(M3DV["0_E?-ARQSA.X.T^P'0
M\TB^&+U6B/\ PD>J-L\O(/E?/M9B<_)_%D X[*,8->19=S]1]I/^3\4=%2US
MEOX8O8#%N\1ZG-L\O._ROGVELYPG\6X9_P!T8QSD3PO?*82?$>J-L\O.?*^?
M:&!S\G\603C^Z,8YHLNX>TG_ "?BCHZ*YZS\.7MK+ [^(-2N1&8RR2^5B3:I
M!#80?>)!.,<@8Q12=NY<9-_$K'0T444C0**** "BBB@ HHHH **** "BBB@
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M<"?FW 'G^!<8YS[C'H%XBQ Z[?N4\O)81?/M5@<_)_$2"<=U&,#.?&_V)/\
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M)96GMY4LUFME&4W2)M)0!E9@6ZYYXXK0GU[34TA-3/Q2MH=-G+K#>F>Q$+'
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M_P!?TW_H9K&Z5[:T1^.5/C84449(JB+!12YH.:+A82BBCF@+!2KU'UI*4?>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEK'PGTKP];QW=[IWAVVB!N+6.1TO"/\ 2IOWB\2'[ZDY_P!HY&!Q1;S#VO\
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MLM3T&\CA:-)VAMY^"02V,MW!3'7OFIX-7\0217,@U30)ELB%O##'*WE%58R
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M^&8X^[LSA_\ >S^&,<T6\P]K_=?W'445RKP^,BS[;G1-O[S9F";(^8;,_/\
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MI3:?J%MJ316.F<JTS21^:H^9 P/R-NW =N/J_ ]*8L$:2-((U$C=7"C)^IH
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M*X2MZ/P(^?S/_>ZGJ%%%%;GEBU^B_P#P3?\ ^22:]_V&'_\ 14=?G/7Z,?\
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MY/\ PC%G]D\C[WD?/L\S/&_KG;QTQ7(8T[_I[_\ '*Z[XE?\BY\,O^Q/L/\
MVI7"5T4G>"/ S*GRXN:NR[C3O^GO_P <HQIW_3U_XY5*BMKGF\GFR[_Q+O\
MI[_\<KW'X%?M9ZC\!/#5YHNCZ):ZE!=71NVEOF8.&*JN!L(&/EKP&BLY1C-6
MDCKPV(K8.I[6A-QEW/L?_AY/XH_Z%72/^_DW_P 51_P\G\4?]"KI'_?R;_XJ
MOCBBL?J]+^4];^WLS_Y_O\/\C[(_X>3^*/\ H5-(_P"_DO\ \51_P\G\4?\
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M[R;/W_\ =_N?^/>U*'\797,6C8R,XDFZ;^<?+_<Q^/M1R^8>U_NLZ; ]!2@
M=,#Z5S"-XNRFZ/1<97=B2;^\=V./[N,>^>U$3>+OD\R+1NJ[MLDWJ=V/E]-N
M/?.:.7S#VO\ =9T^?>ES7+1-XO.SS(M$_@W;9)O??CY?]W'XYI4;Q=M3=%HH
M;Y-V))L=#NQQZ[<?CFCE\P]K_=9T^:7-<L&\7X3='HO1=V))O[IW8^7^]C'M
MFE5O%QVYCT7H-V))NNPY_A_O8_#WHY?,/:_W6=0#SUHS[URV?&&?]5HG3_GI
M-UV?[O\ ?_3WH+>+L'$6C$X.,R38SLX[?W_T]Z.7S#VO]UG49SWI<URS-XP"
MMMBT7/S8S)-_=&W/R_WLY]L=Z5V\78;9'HV?FV[I)L=!MSQZYS[8HY?,/:_W
M6=/NI<URTC>,/G\N+1?XMN^2;VVY^7_>S^%.F/BWY_*CT8_>V[Y)O4;<\>F[
M/X4<HO:_W6=/FDW?A7+N?%^]]D6B[?FVYDF_O#;GY?[N<^^*<[>+<OMCT;'.
MW,DW]\8SQ_=S^/M1R^8_:_W6=-GGK1GWKE]WB_G$6BX[9DF_O_[O]S]?:G;O
M%G'[O1^V?WDW]_GM_<Q^/M1R^8O:_P!U_<=/FC/%<LA\7[DWQ:+CY=V))O[Q
MW8X_NXQ[Y[4Y&\6_N]T6C8^7?MDF_O'=CCTVX]\T<OF'M?[K.FS[TN:Y:)O%
M^Z/S(M%V_)OVR3>^_'R_[N/QS3HV\6_N]\6C9^3?MDF]#OQQZ[<?CFCE\Q^U
M_NLZ?-)FN7B/C#*>9%HF/EW;9)O[IW8^7^]MQ[9I0WBW:N8]&SQG$DW]PY[?
MW\8]L]Z.7S#VO]UG49HS7*AO&&!F/1.V<23?W.?X?[__ ([[T]V\6X.V+1NA
MQF2;KLX[?W__ !WWHY?,/:_W7]QTV:,URY?Q?N;]UHF,-C,LW]P;?X?[^<^V
M.].E;Q9A_+CT8\/L+23==HVYX_O;L^V.]%O,7M?[K^XZ;-+GWKEG;Q?F3;%H
MF/GV;I)O0;,_+Z[L^V,4Z5O%N)/*CT8GY]F^2;G[NS.%_P![/X8HMYC]K_=9
MTQ-&?>N69O%^9-L6B[?GV;I)L_>&S/R^F[/OC%23-XLP_E1Z.>6V[Y)?[XVY
MX_N9S[X[4<HO:_W7]QTV:,URV?%^YOW6B[<MC][-G_6#;_#_ ',Y_P!KVIQ;
MQ9EL1Z/C/&9)NGF?3_GG_P"/>U'+YC]K_=?W'3%J&/!YKEXV\7EAOCT7'&2L
MLV?]9S_#_P \\?\  O:G!O%GR9CT?^'=B27^^=V./[FW'^UGM1;S%[7^Z_N/
MPH\:?\C?K?\ U^S?^AFL:NQ\7+X?_P"$KUKS'U+?]MFSA8\9WGWK)QX<_OZI
M_P!\1_XU[:6A^/U*GOO1_<8E%;>/#G]_5/\ OB/_ !HQX<_OZI_WQ'_C3MYF
M?M/[K^XQ**V\>'/[^J?]\1_XT8\.?W]4_P"^(_\ &BWF'M/[K^XQ**V\>'/[
M^J?]\1_XT8\.?W]4_P"^(_\ &BWF'M/[K^XQ*5>H^M;6/#G]_4_^^(_\:%7P
M[N&'U3/^Y'_C1;S#VG]U_<>U?$G_ )%OX8_]B?8?^U*X2N]\>&/^POA_]KW"
M+_A%[/[+Y/+&#Y]ADST?KD#BN._XEW]ZY_)?\:Z**]Q'@9E/FQ<W9E.BKF=.
M];G\E_QHSIWK<_DO^-;6/-YO)E.BKF=.];G\E_QHSIWK<_DO^-%@YO(IT5<S
MIWK<_DO^-&=.];G\E_QHL'-Y%.BKG_$N_O7/Y+_C2C^SN>;G\EHL'-Y'V?\
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M_P#GS+\/\SI:*YK_ (1_XI_\\_"/_?\ NO\ XBC_ (1_XI_\\_"/_?\ NO\
MXBCVE/\ F0?4<7_SYE^'^9TM%<U_PC_Q3_YY^$?^_P#=?_$4?\(_\4_^>?A'
M_O\ W7_Q%'M(?S(/J.+_ .?,OP_S.GB_UR?[P_G17.VF@_$U+R W$?A00!P9
M#'/=;MN><93KBBLIS@WHSUL%A<1"+YZ;7]>IZW1117FGW84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !2$9I:* ,2Q\$^']+UFZU>RT/3;35KH$
M7%_!9QI/,#_?D"[F_$T_3O!V@Z.TK6&BZ?8M+-]ID-M:1Q[Y?^>APHRW)^;K
MS6Q10!FCPWI*HZ#3+,(ZLK*+=,,&;<0>.06))]^>M0ZEX-T'675]0T73KYUE
M\]6N;2.0B3&W>"RGYL #/7 K8HH Q;+P5X?TW48]0M-#TVUOXT\M+J"SC254
MQC:&"Y P,8S6E;V%M:RSR0V\44D[;Y71 ID;&,L1U. !S5BB@""&QM[>W-O%
M!%' =V8T0!>22>.G)))^M8NI_#SPMK?E_P!H^&](O_*4(GVFPBDVJ!@ ;E.!
MCC%=#10!AIX%\.1WGVM-!TQ+KR/LOGK91!_)QCR]VW.W'\/2MF&&.WB2.)%C
MC0!51!@*!P !3Z* "BBB@ HHHH R_%%E_:/AS4[7["FI^=;R1_8I)?*6?*D;
M"^#MSTSVS7R#I/A?XE/:WFE>%M!\6:=I>FZ,]FL/BF.S6]T]LK_HNF7\9$DJ
M%05#.2H 4[@>*^TJ3 ':@#XK\4?#[X@:_IRW?A;P_P"*-*T^&]N'TJUU:]_T
MZT1K8HQRTK.BL^,*7)ZGH>>Q^#G@KQ+;_%_2]3UGP]XEM]0LK&^M]7U?5;T3
M6=S,\NZ(P R-QLQ@HJ@ $$9KZCP*,4 ?)]_X:\5?#OXH>*-;TSPIXEOK&[UF
MXN)1I#^8+N.:R\N%PK3 '9*/FX&W@T:=\)?'&OV=C=:P_BJSOD&D1E(M<EB\
MN/?)]L!"2[2=I4,><CH:^L, ]J,4 ?'FO>!_B#ID1TXZ7XQU*&..YMO#TMAJ
MSD65R9PT<MPQF5BFS.&D+@#(QG%5-<^%?Q L/"E]J]\OBO4/$UQKDOG1VEW<
M7EI- (D$8^S+=PM'$9-Q5XF!4G+*P&*^SL#THQ0!SOP]34U\$:&NLV<FGZHM
MG$+FVENC<M&X494RGES[G)]S718I:* $Q1MI:* &XZ4N*6B@!,8H I:* &XS
M2XS2T4 (*"*6B@!,=:3%.HH 3&:,4M% ";:,9I:* $Q1BEHH 3%)BG44 )CK
M1BEHH 0BC;2T4 )C-&*6B@!H'-*12T4 )M%&*6B@!,8I"HQ3J0]* /P!\:?\
MC?K?_7]-_P"AFL:MKQG_ ,C=KG_7[-_Z&:Q:]R.Q^-U/C84444S,**** "BB
MB@ I5^\/K24J]1]:!GT)\2?^1;^&7_8GV'_M2N$KN_B5_P BY\,O^Q/L/_:E
M<)6]'X$?/YG_ +W4]?T"EI**V/,"BBBF 4444 %+244@/MS]B3_DD&M_]AYO
M_2:*O?Z\ _8D_P"20:W_ -A]O_2:*O?ZTH_"_4YLT_BP_P ,?R"BBBMSQPKK
M?AM_R%;K_KB/YUR5=;\-?^0K=?\ 7$?SKDQ?\"1]1PS_ ,C?#^K_ "9Z+BC%
M+17RI_28F**6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%%+10!
MYR\_Q7WMLM?"&S)QNN+K./\ OBD\[XL_\^G@_P#\"+K_ .(JE>_M(^#['X_V
M/P?DENO^$LN]-.I(XC7[,!AV6 ONSYS)')($Q]Q"<UV,?Q%\*S:WJ6CQ^)='
M?5],A,]]8+?Q&>TC R7ECW;D7'=@!6O.OY4>?]4E_P _9?>O\CF_/^+/_/IX
M/_\  BZ_^(H\_P"+/_/IX/\ _ BZ_P#B*TH_C7\/9?"A\3IXY\-OX;$_V;^V
M!J\'V3S?^>?F[]N[VSFM>?QYX:M8))Y_$&EPPQVT5X\DE[&%6"0[8I2=V CD
M$*W0D8!-'.OY4'U27_/V7WK_ ".6\_XL_P#/IX/_ / BZ_\ B*//^+/_ #Z>
M#_\ P(NO_B*Z(?$GPH_B/_A'D\3:/)X@/F :4NH1&Z)0 N/*W;LJ"">.,BN*
M^'W[2_A+X@:'IVMH9=!T6_TBVUB&_P!;N+:VCV32R1I$P\XLLF8SU&TY&&)R
M <Z_E0?5)?\ /V7WK_(T_/\ BS_SZ>#_ /P(NO\ XBCS_BS_ ,^G@_\ \"+K
M_P"(K;T;XL>"?$4ZPZ5XPT'4YFM3?+'9ZG#*QMP<&;"L?D!!&[IQUKEO$W[3
M?P\\.:7X?U6/Q'I^LZ/K.MIH*ZGI5]!/:VMPR2.3/*)-J(HB;)R2..*.=?RH
M/JDO^?LOO7^1>\_XL_\ /IX/_P# BZ_^(H\_XL_\^G@__P "+K_XBNXT37-.
M\2Z5;:GI-_;:GIMT@D@O+.99895/1E=20P]P:O8HYU_*@^J2_P"?LOO7^1YS
MY_Q9_P"?3P?_ .!%U_\ $4>?\6?^?3P?_P"!%U_\17HV*,4<Z_E0?5)?\_9?
M>O\ (\Y\_P"+/_/IX/\ _ BZ_P#B*//^+/\ SZ>#_P#P(NO_ (BO1L48HYU_
M*@^J2_Y^R^]?Y'G/G_%G_GT\'_\ @1=?_$4>?\6?^?3P?_X$77_Q%>C8HQ1S
MK^5!]4E_S]E]Z_R/.?/^+/\ SZ>#_P#P(NO_ (BNS\/-K#Z5"=<2SCU+GS!8
M,[0]>-I8 ]/6M/%+4RE?H;4J#IN[G*7K;_(0>]4=<;4ETNX.DK;/J.P^0MXS
M+$6[;BH)Q]*OU5U/4;;2-/N;Z\F2WM+>-I997.%15&23^%0=+5U8X+S_ (L?
M\^G@_P#\"+K_ .(H\_XL_P#/IX/_ / BZ_\ B*K^#OCM8^+M2TZ"3PUXAT/3
M]5MWNM+U75+-4MKR)5WELJ[-#E/G F$9(Z<\5W'AWQ;HGB^R:\T/5['6+17,
M9GL+E)T##J-RDC-:\_\ =1P?5)?\_9?>O\CC_/\ BS_SZ>#_ /P(NO\ XBCS
M_BS_ ,^G@_\ \"+K_P"(K17XP^%)O%DWA^#6;*YO+:UGN[R2&ZB:.S6%D5UF
M.[*-^\'4=CG&*V-)\=^'-=M$NM-U_3+^V='E6:VO(Y%9$(#L"#T4D GMD9ZT
M<Z_E0?5)?\_9?>O\CEO/^+/_ #Z>#_\ P(NO_B*//^+/_/IX/_\  BZ_^(J]
MXD^,_A'P[I>KW@UFSU272K87ES8Z;=137*Q'&&V!LX.0<GCD>M:T?Q$\+2WF
MI6B^(]):[TQ/,OH!?1;[1>YE&[Y /4XHYU_*@^J2_P"?LOO7^1S?G_%G_GT\
M'_\ @1=?_$4>?\6?^?3P?_X$77_Q%;DGQ6\%Q:+_ &P_BW0TTKS&A^W-J,(A
M\Q1EDW[L;@.<=:?!\3_!]U9:A>0^*M%EL].V_;+B/48FCMMPROF,&PN1TSUH
MYU_*@^J2_P"?LOO7^1@>?\6?^?3P?_X$77_Q%'G_ !9_Y]/!_P#X$77_ ,16
M]/\ %+P;:KI[3>*]$A74-ILS)J,2_:<G \O+?-D\<=ZG\(>/=$\<MJZZ->I>
M-I-Z^GW84\QS* 2O_CPY]CZ4<Z_E0?5)?\_9?>O\CFO/^+/_ #Z>#_\ P(NO
M_B*//^+/_/IX/_\  BZ_^(KT;%&*.=?RH/JDO^?LOO7^1YSY_P 6?^?3P?\
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MC,\_XL_\^G@__P "+K_XBCS_ (L_\^G@_P#\"+K_ .(KT;%&*.=?RH/JDO\
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M>$]3@EOO#LFL7/B2+Q!;O_:E_');,=.2SD$=TL>0W[L-\\+HZL4*( *L>/\
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M&\KN]\UT3?#C1G# _;<-NSB^F_B4*?XO0#\>>M#_  YT>16!^V8;=G%],/O
M _Q>@'THM'N'-5_E7W_\ V=%TBS\/:39Z9I\/V>QM(E@@B#%MB*, 9))/'K5
MW=]:YB7X<:-+OW"]^??G%],/O8S_ !_[(^G;K3I?AWH\V_<+SYRQ.+Z8?>()
M_B_V1]/QHM'N+FJ_RK[_ /@'29_SBESUKF7^'.C2%RPO<ONSB^F'WF#'^+U
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M^Z3]3\W7FC^T:?9B_P!1<=_S\C^/^1Y__GI77?#8$:K=<'_4CM[UI+\'_"Z
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M-[816=PE[X+M9KFV9+A)&"N"SE-OE$[RV&5U.%SBM/:3[G#]0PO_ #[1TI^
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MH+[_ ./4?\*$\*_\]=>_\*"^_P#CU>B8%&!1[2?</J&%_P"?:/._^%">%?\
MGKKW_A07W_QZC_A0GA7_ )ZZ]_X4%]_\>KT3 HP*?M)]P^H87_GVCSO_ (4)
MX5_YZZ]_X4%]_P#'J/\ A0GA7_GKKW_A07W_ ,>KT3 HP*7M)]P^H87_ )]H
M\[_X4)X5_P">NO?^%!??_'J/^%">%?\ GKKW_A07W_QZO1,"C I^TGW#ZAA?
M^?:/._\ A0GA7_GKKW_A07W_ ,>H_P"%">%?^>NO?^%!??\ QZO1,"C I>TG
MW#ZAA?\ GVCSO_A0GA7_ )ZZ]_X4%]_\>H_X4)X5_P">NO?^%!??_'J]$Q1@
M4>TGW#ZAA?\ GVCSO_A0GA7_ )ZZ]_X4%]_\>I&^ GA7!_>Z]_X4%]_\>KT7
M H(XI^TGW#ZAA?\ GVC\%_%7B:]M/$VK0(MJ4CNY47=:QL<!R!DD9/U-9?\
MPE]__<L__ .+_P")I/&?_(W:Y_U^S?\ H9K%KV5)V/R6I2IJ;]U&W_PE]]_<
ML_\ P#B_^)H_X2^^_N6?_@'%_P#$UB455V9^RI_RFW_PE]]_<L__  #B_P#B
M:/\ A+[[^Y9_^ <7_P 36)11=A[*G_*;?_"7WW]RS_\  .+_ .)H_P"$OOO[
MEG_X!Q?_ !-8E%%V'LJ?\IM_\)??_P!RS_\  .+_ .)I1XNOR1\EGU_Y\XO_
M (FL.E7J/K2YF'LJ?\J/H;QY*VGZ%\/YH@-]YX8L[J42#> [;\[0<A%XX5<
M=A7'_P!KW'I#_P!^4_PKKOB5_P BY\,?^Q/L/_:E<)712DW!'@YE3A'%S21=
M_M>X](?^_*?X4?VO<>D/_?E/\*I45M=GF<D>Q=_M>X](?^_*?X4?VO<>D/\
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MR"<#'!.!0![?124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_,/J]7_ )_2^Z/_ ,B=_P#\)SXU_P"B;W?_ (-[7_XJC_A.?&O_ $3>[_\
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MED,ODK"8E9A(7P3A1R0*.9?RK\?\P^KU?^?TONC_ /(G>_\ "<^-?^B;W?\
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M "K\?\SA^KU?^?TONC_\B5O^$Y\;?]$WN_\ P;VO_P 51_PG/C;_ *)O=_\
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ML62-L6[C#/[=?E!7-',OY5^/^8?5ZO\ S^E]T?\ Y$^C/^$Z\:C_ )IO=?\
M@WM?_BJ/^$Z\:_\ 1.+K_P &]K_\57*?%+6/&5WHW@2#0-5U;26U)F.I7=OI
MT?VC8+<N-RNCK"2X'&."<5Y3J/Q ^)7@WPK#<:KK_B743J-A:S372Z=;P"RF
M:XV-\XMF$*;,%F*2%>H7FCFC_*OQ_P P^KU?^?TONC_\B>^O\0O&$<BHWP\G
M5VZ*VLV@)_#=4G_"=>-?^B<77_@WM?\ XJOD7_A*OB1?:KHWB.*RO=5UR.$V
MPN[G23+N5+G*'YX(QG;R'"1D@ \9KO\ 0_B%XV\2ZU;Z#I/C7Q+/'+>:2E[=
MW&C0PW-H)E8W(7?;@!=PQN*D+C 8]:.9?RK\?\Q_5ZO_ #^E]T?_ )$][_X3
MKQK_ -$XNO\ P;VO_P 51_PG7C7_ *)O=?\ @WM?_BJ^;O'GQA^)7A_3-)L8
MM1U]=7@@F=;A[%8UO62YV*"B6<IFD\OJB^2N/FW5O6'C/XOP:)<:_#J&KZGJ
M-TVJ1QZ-<Z7$MO"L4:M 4 B5]P);!9SOQC!HYE_*OQ_S%]7J_P#/Z7W1_P#D
M3W%O'OC-653\.KD,W0'6+3)_\>IW_"=>-?\ HF]U_P"#>U_^*KYX\0_$;QN?
M"5CJ?@W5]:\9WL0E9[[5M!6)K1S IE$3BW!.P[N A((V_/C%8M_\9OB3;^&+
M*_7Q5=76GC4)(K=K"SF%Q?J%!")<RZ:(Y'#9Q&88@^<>9D4<R_E7X_YA]7J_
M\_I?='_Y$^H?^$Z\:_\ 1-[O_P &]K_\51_PG/C;_HF]W_X-[7_XJNRT&YDO
MM$L+F:.:*::WCD>.X0)(K%02'4<!@>H'0U?P*.9?RK\?\P^KU?\ G]+[H_\
MR)Y]_P )SXV_Z)O=_P#@WM?_ (JC_A.?&W_1-[O_ ,&]K_\ %5Z#@48%',OY
M5^/^8?5ZO_/Z7W1_^1//O^$Y\;?]$WN__!O:_P#Q5'_"<^-O^B;W?_@WM?\
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M_P"#>U_^*KT' HP*.9?RK\?\P^KU?^?TONC_ /(GGW_"<^-O^B;W?_@WM?\
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M //ZG_?MJ/LEO_S^I_W[:JM%:GFV??\ +_(M?9+?_G]3_OVU'V2W_P"?U/\
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M ,B<#!XU\937$22_#RZ@C9@&D.JVI"#/)P&R<45WV!12<ET7YFD:-2.]5O\
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M$L>0K,N#G(^D@,4<49H 6BDS1F@!:*3-&: %HI,T9H 6BDS2T %-V\4N:,T
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M_P"A-TO_ +\G_&C_ (9V^&I_YDS2_P#OR?\ &BU/N_N_X(<^,_DC_P"!/_Y
MZ>X\&:3=^)=*UN6(&[TJ&:*S0$".$R[0[A0/OE5VY]&8=S6]O7'WA^=><_\
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M?_R!Z+O7^\/SHWK_ 'A^=>=?\,Z_#7_H3-+_ ._)_P :/^&=?AK_ -"9I?\
MWY/^-%J?=_=_P0Y\9_)'_P "?_R!Z+O7^\/SHWK_ 'A^=>=?\,Z_#7_H3-+_
M ._)_P :/^&=?AK_ -"9I?\ WY/^-%J?=_=_P0Y\9_)'_P "?_R)Z+O7^\/S
MHWK_ 'A^=>=?\,Z_#7_H3-+_ ._)_P :/^&=?AK_ -"9I?\ WY/^-%J?=_=_
MP0Y\9_)'_P "?_R)Z+O7^\/SHW ]"*\Z_P"&=?AK_P!";I?_ 'Y/^-=1X1\
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M?( Q ^4L3U (YJE-XL^ BW]S;0_#ZZNECO#80W,6D$6]Y.%#LD$K.JR$*0V
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MZ_WA^=>=?\,Z_#7_ *$S2_\ OR?\:/\ AG7X:_\ 0F:7_P!^3_C1:GW?W?\
M!#GQG\D?_ G_ /(GHN]?[P_.C>O]X?G7G7_#.OPU_P"A,TO_ +\G_&C_ (9U
M^&O_ $)FE_\ ?D_XT6I]W]W_  0Y\9_)'_P)_P#R!Z+O7^\/SHWK_>'YUYU_
MPSK\-?\ H3-+_P"_)_QH_P"&=?AK_P!"9I?_ 'Y/^-%J?=_=_P $.?&?R1_\
M"?\ \@>B[U_O#\Z-Z_WA^=>=?\,Z_#7_ *$S2_\ OR?\:/\ AG7X:_\ 0F:7
M_P!^3_C1:GW?W?\ !#GQG\D?_ G_ /('HN]?[P_.C>O]X?G7G7_#.OPU_P"A
M,TO_ +\G_&C_ (9U^&O_ $)FE_\ ?D_XT6I]W]W_  0Y\9_)'_P)_P#R)Z+O
M7^\/SHWK_>'YUYU_PSK\-?\ H3-+_P"_)_QH_P"&=?AK_P!"9I?_ 'Y/^-%J
M?=_=_P $.?&?R1_\"?\ \B>B[U_O#\Z-Z_WA^=>=?\,Z_#7_ *$S2_\ OR?\
M:/\ AG7X:_\ 0F:7_P!^3_C1:GW?W?\ !#GQG\D?_ G_ /('HN]?[P_.C>O]
MX?G7G7_#.OPU_P"A,TO_ +\G_&C_ (9U^&O_ $)FE_\ ?D_XT6I]W]W_  0Y
M\9_)'_P)_P#R!Z+O7^\/SH+KC[P_.O.O^&=?AK_T)FE_]^3_ (T']G7X:_\
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M4^[^[_@G]$<^,_DC_P"!/_Y$]%WK_>'YT;U_O#\Z\Z_X9U^&O_0F:7_WY/\
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MOQTUCPEI5I+>_#IM/\37FO?V.;74-5M[6UE86DEPMS%>LNV2/RXRGW0P?*$
MCF#L/CGXJ?M*>.O'_P"SQ\0[67Q9IOB>U3PWH>NRZ]X:LIM,&C7T^HQI-IDK
M)*SDK&"QY60*&W+S5SX5?&?6OAAI'Q:N/"7B#2M1T<W_ (?CBURQN=0U?0-!
MAN97@N;DBZ<S-+&/WCH)-F!&>.17UD/VCK#P]K'@;2/%/AB+1O\ A,;B]3[7
MI]_#J%E:R1/"D;3RQJ!B:29(PV/E<H&^\"-.?]H73+'0[*<>%M4FCO?%DWA0
M1VL(>&%DU#[&UQ/( $CC)(8*?F;(4 G. #Y[C_:R\=76G^'K.X\6^&])T2X\
M0ZUI8^(L^BR-I^JQ6=O#);"*+S JF=Y9H\J[!C:MLR6Q6'\!/C]\2M%\-?!_
MX>0,=2U#QKI6DWVC:G>VC2M;VT3RG6!-([_O72..-DS@_O\ OM /U5#\;+*7
MQQ'X?/AF=/#,>K_\(_#KK/$(1J21><(Q!]X1C&P2C_EH,8 PU<)I/B?1/%7Q
M*\9>/O"'A#4/%'B'PWY6AVDU_K?V6R-K(@DGFLTES'&A* ,X4>9Y>02N"0#S
M3XP?$:7Q9\3/!$7QV\.ZW\*/ABUKJ0\B\UT);WFHJ(#;M/<6,GRCRVN-B.ZY
M93P2!7'>(_$OPHO/&/PT7Q;XM\56/PRG\!ZC-I=UXCU?4+*^FG6_B6!V:)U=
MW\LR^7NSF/:>>*^L_AY\;E^(ND^$)=<\)3:%;>*S="P%S/'=12F'YXSE5QB6
M)))8R>JQ^I%>NR6D,SH\D2.Z_=9E!(^AH _-N_\ %VI6?A3X&ZQKGB3Q"/BG
M!_9+RZ1<WM[#?W^FOJ$B1&T@!%O-/)$4^T&5781J,A20:Z+Q_P#M(>./%FF?
M'KPE=ZY:+H^A^'M<?0=7TW39[2;7'BPKF&7.T-9D^6QC/[QB&& IK] GM()9
MHY7B1I8L['9067(P<'MD4TZ?;%44V\15,[04&%SUQZ4 ?F!^SKK^@ZAJ'BG3
M]<U>3Q-X-?X?QZOJEMX2U_5Y8X;FV=)6:YDEE\R*Y/W0(752-X(->C^#_!GC
M;X;R_LYVWA+4@WB/Q))K&N7MKK^I7USI\9FL/,6W)\QI"D4>Q$W$_,I8\DU]
M]1V4$4;(D,:(WWE5  ?J*?Y,>4.Q<IPIP/E^GI0!^6/Q)^*/Q7LO@1=Z>+#Q
M*]C!XLU6[UC7_#RO+$TZ:N$BL5D>59(X"-[="2%B3@,Q'ZC:5>MJ6F6EXUM/
M9-<1)*;:Z4++#N4'8X!(##." 3R#R:F-K"4*&)"A.2NT8)ZU)TH 6BBB@ HH
MHH *Y_X@3:Q;^"-=E\/QK+KB64S62/T:8(=@_/%=!10!\/>%/B#X<\,:[\/I
MO"-J?$GBB\LW&K36WB>9]6^V?9Y'G74=/9&)C#H>79-C;0H  SI_##]H;XD?
M$2&QM%U;1;6>_N=.26ZA6VOI+-IQ(9HO+A?:A4* JRGS%(.\&OL:/3[:&YEN
M8[>)+B8 22J@#OCID]3CWHAL+:VW>5;Q1;G,C;$ RQZL??WH ^0W^.7Q/U#0
MKBXM-9TVUGTG3+VYE:31]XO9H-2DM5W#>-BM&F2%YR<@XXJ3XD_M!>+OA\=4
M\/W7B:W_ +7L=1NXX+]M,MK=+J*.V@E =YI5C4AIB-J!Y' ^51AC7UW]FAY_
M=)SP?E'KFFS6-M<,C2V\4C(_F*70':W]X>A]Z /C3X1_&37I_B=>3#Q98W=Q
MK^NZ8'\)- 9)?(FT^W:>XA8MO2-&9FX&P;&!Y/'VB.14*6-O%*)$@C20+M#J
M@! ],^G J>@ HHHH **** "BBB@ HHHH J:MID6LZ9=6-P9!#<1M$YBD:-P"
M,'#*00?<5XNW[*NGZL[-XE\8>(_%3V]D]AI4NH/;K+IL;$'<DD<2M+(-J_/*
M7/'/))KW.B@#PO6_V4=+\4V;_P!N>*=<U74YYGFN=1E^SJ\Q:(Q!=BQA$55)
MP% Y))K?\$? .V\$^*[35HO$VM7]G80SV^G:3=M";>TCF;>X!5 [G=G!=B0#
MCI7JM% 'CGB+]G"WUCQ)J6MV'BW6]#O;R\-Z#9I;.(7>$PS!?,B;(=.#NS@C
M*XJYH?[/.D:%806L6JZE,D+V#AYC&68VC,4R0H^]O.[],5ZO10!XMJO[,.FW
MTMTUKXFUO3(]0\Z+4XK8P%;VWDD#F$[XVV8(X=,-@D9I-3_9=T6Z\$W'ABRU
MF_T_3IM0EOFB\BVN(B'14,1BEB9&50HVL1N4\@YKVJB@#&\'>%[;P5X8TO0K
M.6XGM=/MTMHI+J3S)&51@%F[FMFBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]*!
M'X!>,_\ D;M<_P"OV;_T,UBUM>,_^1NUS_K]F_\ 0S6+7MQV/QRI\;"BBBJ,
MPHHHH **** "E7J/K24J]1]: /H3XE?\BW\,?^Q/L/\ VI7"5W?Q*_Y%SX9?
M]B?8?^U*X2MZ/P(\#-/][J>O^04445N>6%%%% !1110 4444AGVY^Q)_R2#6
M_P#L/M_Z315[_7@'[$G_ "2#6_\ L/M_Z315[_6E'X7ZG-FG\6'^&/Y!1116
MYXX5UOPU_P"0K=?]<1_.N2KK?AK_ ,A6Z_ZXC^=<F+_@2/J.&?\ D;X?U?Y,
M]&HHHKY4_I,**** "BBB@ HHHH **** "BBB@ HHHH **** /G_3/@CKUM-=
MC3+Y= UC0?$VHZSH6J7$'VNUO+:_#2303Q[U<C?*Z'#*P,4; D<5E0_LJ:I;
MZ;'-'J7A5=5_MZ+6FT[_ (1UCHR!+*:U$2VQG+%B)S(9&?)95X  KTI[_P"+
M(D;9HWA(IDX)U&YSCMG]U2?VA\6_^@-X1_\ !C<__&JU]F^Z^\\_ZY'^27_@
M+,&/]GT>(9=*_P"$L?0[BPMM)U71[G2M#TMK&TGAO'MFR%,C%&7[.3D'DL"-
MI6F>#_V>+OPS\)['P=>>*I];N[?Q*GB"36;NW FN=NI"]VR -@N0NPOW)+8[
M5T/]H?%O_H#>$?\ P8W/_P :H_M#XM_] ;PC_P"#&Y_^-4>S?=?>'UR/_/N7
M_@+.;U3]G:ZUGQ)>P77B'_BBKG6)_$#:;# T5\MW+;M"R+=*XVQ!F:4$*'#'
M&[:*S[#]E&'P_P"'?B'H^B>+=7MK?Q3I\&F0?;9WNQI\,< APH=L,=F0#Q@8
M':NT_M#XM_\ 0&\(_P#@QN?_ (U1_:'Q;_Z WA'_ ,&-S_\ &J/9^:^\/KL?
M^?<O_ 62>+?!MSJWC/X=6=AIR6WA[P]=2:G+/&0BQF.V>W@@10>_GENF L6.
M"17HZC KS3^T/BW_ - ;PC_X,;G_ .-4?VA\6_\ H#>$?_!C<_\ QJCV;[K[
MP^N1_DE_X"STRBO,_P"T/BW_ - ;PC_X,;G_ .-4?VC\6_\ H#>$?_!C<_\
MQJCV;[K[P^NQ_P"?<O\ P%GIE%>9_P!H_%O_ * WA'_P8W/_ ,:H_M'XM_\
M0&\(_P#@QN?_ (U2Y'W7WA]<C_)+_P !9Z917F?]H_%O_H#>$?\ P8W/_P :
MH_M'XM_] ;PC_P"#&Y_^-4_9ONOO#Z['_GW+_P !9Z917F?]H_%O_H#>$?\
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MMQ;RJ'CEBU.X9'4\@@B/D5-_:/Q;_P"@/X1_\&-S_P#&J/9^:^\/KL?Y)?\
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M_P"->RHZ;GY)4K)R?NO[F8M%;?D^'?\ GZU+_OQ'_C2>3X=_Y^M2_P"_$?\
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M$^#/"<?C/QAK%K<Z@+:YU1=/M;6T@*+)++-LD.2TB(JJAR2<D $UQ>L_M/\
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M<7<,<9^6US(HV%,[ 2,-G-?45A91:;96]I NV""-8HU)SA5  'Y"@"Q1110
ME&*6B@!!Q6=XCU^S\+:#J&L:C*(+&Q@>XGD/\**"6/Y"M*L_7]#L_$VB7VDZ
MA"+BQO87MYXFZ.C AA^1H \L\(?&?Q1K-_H=UK'@RTTCPYK5NUW!=PZVEQ=V
M</E^9')=P&-0BLHY,;R;20#W(T7_ &F/A[%IS7LFM7$<)D@BB1M,NA+<><2(
M&AC\O?*DA!".@*L>AKBE_9,EU;6?#S^)?%PUW2/#L9ATN-=%M[>_\L1-%&D]
MXI)D55=N%1,G!.><S_#[]D^V\"WNF7"ZS:.=.EM##]CT>.V:6. .%$KAV9W;
M<,L"J_+E44DT =)J?[5GPPT>RL;NZ\2-'!>6S7B.-/NG\J%9/*=YML9\D+)\
MC>9MVMP<5<E_:2\!Q:*FI_VE?20F>6!K>/2+Q[J-HU#R%X!%YB*J,K%F4+AE
M.>17+V?[+,%IIFK6?_"1SO\ VA9W=H7-HN4$]\]V6^_S@OLQW S[5'\0OV6Y
M/'>N:I?#Q7);6NHW4]S/IEU9?:+7,EO#"'\L2H&E3R<JS[E&]@4/!H VO!G[
M37ACQ9XYU?PR\C6<UO?PV5A=B.62WOO-MHYXR)1&(T9A)A4+9...N*]AKP3P
M7^S#?^%M3MA<^-'U'0X[^QU233ETM(G>XM;>*&,^;YAPA,*.5VDY& P&:]\H
M *2EHH **** "BBB@!* ,4M% ',_$K3[C5?A_P"([.TA>YNI]/GBBA099V,9
M  'J37RII7PJ^*/A/2O T^Z]UJ^M/"CV^D>3IUM:MHFH_90I2YV -(I7<BDG
M <#<"3D?:-)M'H* /A^/P]\38;?3]1BL/&'B1=/<SQ6UW#/:7$,[6<BRF.:Y
MGFEY<@$J @/^K'-4;;4_&^F^)M+T7Q!-X_CT*]O96MK;2WU".YN,64C,%,LK
M7+1K(%)R5&1G:!FONX* ,8&/I5>;3K6>X@GDMH9)X,F*1XP63(P=IQD9''%
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M?HVC>.-&N9/$.K6-YX9A>W.M7CWCR7SVY$R(TC$@EC@J,+GH*^B-H]!01[4
M?%&EV?Q(>TG\!Z7JFNVO]B:;;:B38W02ZC:98T^QDC[OEX=@#V-;WBCP=XU^
M'VF>(-;L]=\:-':7-]'$U]K$MQ%%9>1E'"NQ!^?D.V6![XXKZJT[0=-TB>\G
ML=.M+*:]D\ZZDMX%C:>3&-[D#YFQW/-6[FUAO('AGB2:&0%7CD4,K ]00>M
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MA"*'2,8B_=>:ZMDL6%?9>GZ_X(T?4]4O;76M(M[K4I4FO&&H1_O9518PY&[
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MR:1_X'1?_%4?\+#\+_\ 0R:1_P"!T7_Q5'++L'MZ7\Z^]'145SO_  L/PO\
M]#)I'_@=%_\ %4?\+#\+_P#0R:1_X'1?_%4<LNP>WI?SK[T=%17._P#"P_"_
M_0R:1_X'1?\ Q5'_  L/PO\ ]#)I'_@=%_\ %4<LNP>WI?SK[T=%17._\+#\
M+_\ 0R:1_P"!T7_Q5'_"P_"__0R:1_X'1?\ Q5'++L'MZ7\Z^]'145SO_"P_
M"_\ T,FD?^!T7_Q5'_"P_"__ $,FD?\ @=%_\51RR[![>E_.OO1T5%<[_P +
M#\+_ /0R:1_X'1?_ !5'_"P_"_\ T,FD?^!T7_Q5'++L'MZ7\Z^]'145SO\
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M:Y_U^S?^AFL6O:BW8_(*D8\[T+O]N:C_ -!"Z_[_ #?XT?VYJ/\ T$+K_O\
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MPKOPO_T+>D?^ ,7_ ,37145X?-+N?L_L*7\B^Y'._P#"N_"__0MZ1_X Q?\
MQ-'_  KOPO\ ]"YI'_@#%_\ $UT5%'-+N'L*7\B^Y'-O\-_"DF-WAG1VQ_>L
M(C_[+3?^%9^$O^A7T7_P7P__ !-=-11S/N/V%+^5?<CF?^%9^$O^A7T7_P %
M\/\ \31_PK/PE_T*^B_^"^'_ .)KIJ*.9]P]C2_E7W(YG_A6?A+_ *%?1?\
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MVZ^4T2K)=)$)9E5'( 8CH-V['-OX??LIZ+X!FL9(-5>;[!/;R6P@TVTM"8X
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MC[+[@^IK^>7_ ($ST[^P_BM_T-GA?_P0S?\ R31_87Q6_P"AL\+_ /@AF_\
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MY@@RQ1%+''Y5)TM75CC_ .P_BM_T-GA?_P $,W_R31_87Q6_Z&SPO_X(9O\
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MC[+[@^IK^>7_ ($SS7^POBM_T-GA?_P0S?\ R31_87Q6_P"AL\+_ /@AF_\
MDFO2J*/:/LON#ZFOYY?^!,\U_L+XK?\ 0V>%_P#P0S?_ "31_87Q6_Z&SPO_
M ."&;_Y)KTJBCVC[+[@^IK^>7_@3/-?["^*W_0V>%_\ P0S?_)-']A?%;_H;
M/"__ ((9O_DFO2J*/:/LON#ZHOYY?^!,\U_L+XK?]#9X7_\ !#-_\DT?V%\5
MO^AL\+_^"&;_ .2:]*HH]H^R^X/JB_GE_P"!,\U_L+XK?]#9X7_\$,W_ ,DT
M?V%\5O\ H;/"_P#X(9O_ ))KTJBCVC[+[@^IK^>7_@3/-?["^*W_ $-GA?\
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M_DFC^POBM_T-GA?_ ,$,W_R37I5%>)[1]E]Q^Q?5%_/+_P "9YK_ &%\5O\
MH;/"_P#X(9O_ ))H_L+XK?\ 0V>%_P#P0S?_ "37I5%'M'V7W!]37\\O_ F>
M:_V%\5O^AL\+_P#@AF_^2:/["^*W_0V>%_\ P0S?_)->E44>T?9?<'U-?SR_
M\"9YK_87Q6_Z&SPO_P""&;_Y)H_L+XK?]#9X7_\ !#-_\DUZ511[1]E]P?5%
M_/+_ ,"9YK_87Q6_Z&SPO_X(9O\ Y)H_L+XK?]#9X7_\$,W_ ,DUZ511[1]E
M]P?5%_/+_P "9YK_ &%\5O\ H;/"_P#X(9O_ ))H_L+XK?\ 0V>%_P#P0S?_
M "37I5%'M'V7W!]37\\O_ F>:_V%\5O^AL\+_P#@AF_^2:/["^*W_0V>%_\
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M[,7P[T;Q'XCU_7/'6L)X?_X2$>,-6\/7VL0P:1%?,R.DUPH56V!HD94D?9E
M<'%8DOP(^".ERKX\U?XCI<>"KW5=7O+.VU'Q!:KHGG:G;RP7T<<F!O\ ,WRL
M 9"5.X+@;@:ATVZN-0@\0:]H5WXIL='^(&LR>(=.L;5[V2!S$T6GW/V;!:9(
MH#;X558J)5D ^3(YG7M&US5K"'4HO#\NB:</&T5Z=8TKP#<[KD?V5<PR7#Z7
M,\K;=_DQ"7:F<AMI(#&#K.IT3]EOX1?$3P=J6D0_$S4/&RZ]IL&BZ?JJ:[:W
M5S:Z?87"3K;6KQIM98I3&7=@[_,NYNE=0?V7/ FJZ9X@U'5O'6O^(=:U*\L+
M?_A*[W6(3=V%U971-K' T:+%&\=PY&TH278JP).*XG4OAAK/Q U[X:ZAH4U^
MFL^'=/UV[T[Q#=^'9-$BM]1\ZR\I)K;8H$<L?G1,,?O$,A'*Y$WAKX>:KXQ^
M#/A_6-?\$ZEI/BFU^))UR+2+D2-)IXDUT222%5.QU6(N1*01L)8$9S0!U47[
M+O@2'6=/TNR^(&NV?Q&L[N[UZZU>VU>!=9O!>)'#=/+%L*K%(D,2#9&H3RD*
M%2N:X;P=^SYX-T?XQ>"O$=GK_AN3P#\*M ?3HKQ]=2YN[B1BWE->H%6*%8"U
MPR-N)+/GC;6_/X4U*+XE3V\/AG4AXJ3QO<ZZ-<BT_=&^FFP95*W; 1\C;;B(
MOG<!E0OS5PEAX U:W\(IIFCV?B*?PKH46@ZC&=>\)I%/'J,$Y#VL]M!%$]U;
MHF'E*>:4;#(TG(H ]>\9_ #X7Z?)HWC?0/%D?PAM+2TN8H]3\)W%AIUI=13B
M.21G9XV1\BV1MP[)G.!7GM[^S_X=^*OC;4?$-[\8GUKX?ZGH.G>%;B^L-?M6
MFUJ9;R9VMKITC\L^9YT:+Y160Y91]XYXSQC\+_&VN_ KQO:3Z%J%\5M-:U32
M[*WTB2,!KV]588X+5@6!6**X?RS\RK<+N +$4_6/A5K?C^7Q'I<FC:SK7AC5
M]=\+K-JI\-/H$Y2*^?ST6W5$)6*)_,-SM!!8+DA!M /8/B+\$_A/X8\7WVIZ
MY\3+CP)HNJ:A:ZEJGA9O$4&GZ;?WB*/(D97Q(A(MQE8W42>5R#MK)TK]F_\
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M9)->4:5X.\3>!/AA\:8-;T2XTO4IM:LK[3-02]-U/?ZD8;7;-&QB3<3.!R.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "QC_P"^!1[G9ARXS^>/_@+_ /DC@_\ AH/X<G_F;],_[^G_  H_X:#^'/\
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MNS+$D<'@$T>YV?W_ / #EQG\\?\ P%__ "1Z+_PT)\.?^APTS_O[_P#6I?\
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M_0WZ9_W]/^%=Y]BM_P#GA'_WP*/L4'_/&/\ [X%>)>'9_P!?(_8N7&?SQ_\
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M-X7T6[O=2\-:S8RV5])87=K=2V,!@D6-)>9'N5C;<DBE55V8G(V\&@#P?6_
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M_P#C%'_"T?'7_0XWW_@'9?\ QBCZI/N'^LF$_DE]R_S/K3-&:^2_^%H^.O\
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M_P _>K?]_H__ (W6M/W8I'E8W]_B)U([,^5:*^JO^&8/"?\ S]ZM_P!_H_\
MXW1_PS!X3_Y^]6_[_1__ !NM;HX?92/E6OT7_P"";Y_XM)KW_89?_P!%1UXE
M_P ,P>$\X^UZM_W^C_\ C=>A_#FRU+X-:1/I/A3Q%J-A8W$QN9(WBM927( )
MR\)/0#BN7$1=2GRH^AR+$1P&,5:JKJS6GG]Q]P9HS7R7_P +1\=?]#A??^ =
ME_\ &*/^%H^.O^APOO\ P#LO_C%>7]4GW/TC_63"_P DON7^9]:9HS7R7_PM
M'QU_T.%]_P" =E_\8H_X6CXZ_P"APOO_  #LO_C%'U2?</\ 63"_R2^Y?YGU
MIFC-?)?_  M'QU_T.-]_X!V7_P 8H_X6CXZ_Z'"^_P# .R_^,4?5)]P_UDPO
M\DON7^9]:9HS7R7_ ,+1\=?]#C??^ =E_P#&*/\ A:/CK_H<+[_P#LO_ (Q1
M]4GW#_63"_R2^Y?YGUIFC-?)?_"T?'7_ $.%]_X!V7_QBC_A:/CK_H<+[_P#
MLO\ XQ1]4GW#_63"_P DON7^9]:9HS7R7_PM'QU_T.%]_P" =E_\8H_X6CXZ
M_P"APOO_  #LO_C%'U2?</\ 63"_R2^Y?YGUIFC-?)?_  M'QU_T.%]_X!V7
M_P 8H_X6CXZ_Z'&^_P# .R_^,4?5)]P_UDPO\DON7^9]:9HS7R7_ ,+1\=?]
M#A??^ =E_P#&*/\ A:/CK_H<+[_P#LO_ (Q1]4GW#_63"_R2^Y?YGUIFC-?)
M?_"T?'7_ $.%]_X!V7_QBC_A:/CK_H<+[_P#LO\ XQ1]4GW#_63"_P DON7^
M9]:9HS7R7_PM'QU_T.%]_P" =E_\8H_X6CXZ_P"APOO_  #LO_C%'U2?</\
M63"_R2^Y?YGUIFC-?)?_  M'QU_T.%]_X!V7_P 8H_X6CXZ_Z'"^_P# .R_^
M,4?5)]P_UDPO\DON7^9]:9HS7R7_ ,+1\=?]#A??^ =E_P#&*/\ A:/CK_H<
M+[_P#LO_ (Q1]4GW#_63"_R2^Y?YGUF3[XHKY7TCXF>-I]5LXY?%MY+$\\:L
>C6EF P+#(X@!_*BHEAY1ZG90SJA73<8O3T_S/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gmab-20240502xex99d1006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &= Z@# 2(  A$! Q$!_\0
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MMX:O+.#3T*,ZO<R2(%@4JC$,Y .#B@#WFBN5_P"%K^"?^$2_X2K_ (3'0/\
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M;PA^U-X"\9Z=?W%K=7^FW6GWUKI]YI>MV3Z=>V\ERVVW+PSA&"N<[3WP<9-
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)I5@ADE<X1%+$^PH
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M%% !1110 5\[_M$_L[ZA\;?C9\(M5-UJ>G>&O#]KK::G?:)J\FG7D3W$=J(
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M#%.FQ6CYF!<R.X!3Y<?Q?H510!^<\W[$_P 2/[,L] D\&^&-4N=8TGP[;?\
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MTJ'P;I,&NZ[I7B32=;CTZXO%M$N%M;N.=D\U@0F0F,X.,]#TKQ'Q'\ /BO\
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M^U]JOCG5[*272/[9U+5[;Q#!K-HHFCN2VRV>V%D;AMJN$PUQL&S( X%?<E%
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MUNUN;75<3!_.%O%90NN-I(>>5Y )-O.3M^X** "BBB@ HHHH **** "BBB@
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MJ+5?VGO"OAVXO;;5([UKBT34;J5-,M9KH16EE*L4\\AV+M"EUR.>O!:J>L_
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M^A/_  I;P9_T!5_\"9O_ (NC_A2W@S_H"K_X$S?_ !=?%GAOXZ^+_$.B>/\
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MF7U#!_\ /F/_ ("O\CZ8_P"%+>#/^@*O_@3-_P#%T?\ "EO!G_0%7_P)F_\
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M=O11[2?\S#ZA@_\ GS'_ ,!7^1Q'_"EO!G_0%7_P)F_^+H_X4MX,_P"@*O\
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M]+_L?+?^@:'_ (!'_(ZW_A;7C/\ Z&?5/_ EO\:/^%M>,_\ H9]4_P# EO\
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MKQQ_K!^3>AHY6/VU/^8V:*Q&\66Z0O(;/42$&2!9OD_*S<#'/W#^) [BI?\
MA)(/M'D_9;[=NV[OLK[?O;>N.F>?IS1RL/;4W]HUJ*PT\76SVZRBRU$*PSM-
ME(&^Z&Z8_P!K'U!':I&\3P+)(GV2_)0X)%H^#RXX..?N'\U]11ROL+V])_:-
MBBL8>*;<M$OV2_S(<#_1'P/N=>./]8/R;T--;Q9;I"\AL]1(09(%F^3\K-P,
M<_</XD#N*.5]@]O2_F-NBLG_ (22#[1Y/V6^W;MN[[*^W[VWKCIGGZ<U"GBZ
MV>W6466HA6&=ILI WW0W3'^UCZ@CM1RL/;TU]HW**QV\3P+)(GV2_)0X)%H^
M#RXX..?N'\U]12#Q3;EHE^R7^9#@?Z(^!]SKQQ_K!^3>AHY6/VU/^8V:*Q&\
M66Z0O(;/42$&2!9OD_*S<#'/W#^) [BI?^$D@^T>3]EOMV[;N^ROM^]MZXZ9
MY^G-'*P]M3?VC6HK#3Q=;/;K*++40K#.TV4@;[H;IC_:Q]01VJ1O$\"R2)]D
MOR4."1:/@\N.#CG[A_-?44<K["]O2?VC8HK&'BFW+1+]DO\ ,AP/]$? ^YUX
MX_U@_)O0TUO%END+R&SU$A!D@6;Y/RLW QS]P_B0.XHY7V#V]+^8VZ*R?^$D
M@^T>3]EOMV[;N^ROM^]MZXZ9Y^G-0IXNMGMUE%EJ(5AG:;*0-]T-TQ_M8^H(
M[4<K#V]-?:-RBL=O$\"R2)]DOR4."1:/@\N.#CG[A_-?44@\4VY:)?LE_F0X
M'^B/@?<Z\<?ZP?DWH:.5C]M3_F-FN&^._P#R0_XA_P#8NZC_ .DTE;S>++=(
M7D-GJ)"#) LWR?E9N!CG[A_$@=Q7&_''Q!#-\'/B!;"VO%=M U! [6SA ?)=
M,EL8 R<Y].:TIQ?/'U+I5Z2G%N2W1^(-%:/]AR_\_%I_X$+_ (T?V'+_ ,_%
MI_X$+_C7Z#<_2/[3P7_/U?>9U%:/]AR_\_%I_P"!"_XT?V'+_P _%I_X$+_C
M1</[3P7_ #]7WF=16C_8<O\ S\6G_@0O^-']AR_\_%I_X$+_ (T7#^T\%_S]
M7WF=16C_ &'+_P _%I_X$+_C1_8<O_/Q:?\ @0O^-%P_M/!?\_5]Y[9^R[_R
M!/B-_P!@^T_]*DKOJX+]G)?[(TCQZDA$YGL;95-M^]"XN5/S8^Z/KWKM?MB_
MW)?^^#7MY=.*A.[Z_HCZ#*\UP,:<[UE\7?R18HJO]L7^Y+_WP:/MB_W)?^^#
M7J^TAW/9_M? ?\_H_>6**K_;%_N2_P#?!H^V+_<E_P"^#1[2'</[7P'_ #^C
M]Y8HJO\ ;%_N2_\ ?!H^V+_<E_[X-'M(=P_M? ?\_H_>6*]L\-?\DS\-?]=+
MO_T8*\+^V+_<E_[X->O^'_$4,7P]\/P&UO6:-[DEEMG*G,@Z'&#7FXZ<7&%G
MU_1GD9EFV!E"%JR^+OY,V:*R?^$CA_Y];[_P%?\ PH_X2.'_ )];[_P%?_"O
M+YD>/_:F"_Y^K[S6HK)_X2.'_GUOO_ 5_P#"C_A(X?\ GUOO_ 5_\*.9!_:F
M"_Y^K[S6HK)_X2.'_GUOO_ 5_P#"C_A(X?\ GUOO_ 5_\*.9!_:F"_Y^K[S6
MHK)_X2.'_GUOO_ 5_P#"C_A(X?\ GUOO_ 5_\*.9!_:F"_Y^K[SZ.O\ _7K_
M -<H_P#T!:KUA7OCVT:93_9VKC]W&.=.E_N#VJO_ ,)W:?\ 0.U?_P %\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*R6QP'+1EI1M8;/NFOK-<A1N(+8Y(&!0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<-\=_^2'_$/_L7=1_])I*[FN&^._\ R0_XA_\
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M_,N9;@P 1L9)0B1;"6P22O )[1]E]R#ZG3_FE_X'+_,^B?[*^(?_ $,?A_\
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M-/N1QSPL)R<G*6O:4E^IZ-_97Q#_ .AC\/\ _@FF_P#DFC^ROB'_ -#'X?\
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M$_+S3]H^R^Y&7U.G_-+_ ,#E_F>B?V5\0_\ H8_#_P#X)IO_ ))H_LKXA_\
M0Q^'_P#P33?_ "33/@_XKU3Q1X=U"'6I(;G5='U.YTBXO+>/RDNC"V!,$R0I
M92I*@X#9QQQ7=4>T?9?<@^IT_P":7_@<O\SB/[*^(?\ T,?A_P#\$TW_ ,DT
M?V5\0_\ H8_#_P#X)IO_ ))KMZ*/:/LON0?4Z?\ -+_P.7^9Q']E?$/_ *&/
MP_\ ^":;_P"2:/[*^(?_ $,?A_\ \$TW_P DUV]%'M'V7W(/J=/^:7_@<O\
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MZEA_Y#C/^%90_P#0Q^)/_!H]'_"LH?\ H8_$G_@T>NSHH]I+N'U+#_R'&?\
M"LH?^AC\2?\ @T>C_A64/_0Q^)/_  :/79T4>TEW#ZEA_P"0XS_A64/_ $,?
MB3_P:/7'?&?X>Q:?\'O'5T->U^<P:#?RB*?47>-\6[G:R]U.,$=Q7LE<-\=_
M^2'_ !#_ .Q=U'_TFDK2G.7.M>IK2P.']I'W.J/P^_MMO^?.R_[\"C^VV_Y\
M[+_OP*SJ*^_LC]._LS"?\^U^)H_VVW_/G9?]^!1_;;?\^=E_WX%9U%%D']F8
M3_GVOQ-'^VV_Y\[+_OP*/[;;_GSLO^_ K.HHL@_LS"?\^U^)H_VVW_/G9?\
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MBLS8DVNPHN^X>RIK[*^X^LKS2?#VFQPRW5EIEJ@D6*-YHHT&]B@55)'4E8P
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M^CGBU-KZ 2+"[D-$#$;L2" B-5$1&.#1=]P]E3_E7W'U\OA715B$8T>P$8&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS,/8Q??[W_F;K:-J!ED8:Y<!6.500Q_+R_ ^7T91_P  'J<G]CZCF(_VY/\
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M.8DD<$JTBH'.X@GDYKCX-_#.32I[:>R@OX;DN\US?ZI-=7$V^V>W.^>25I'
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M2BN+_P"%A:E_T(7B;\K/_P"2:/\ A86I?]"%XF_*S_\ DFCV<OZ:#Z[1\_\
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M_P +"U+_ *$+Q-^5G_\ )-'_  L+4O\ H0O$WY6?_P DT>SE_30?7:/G_P"
MR_R/$_$%YXG'C?4/(O/%0\7KXDD2*TBFNAIG]C>2<-Y>?L^-O._'F>9@9[5I
M6.E>*--_8GTDP:EXH/C2^T#3;FZO)[VYGU-+N58#.09&9T8$O\@P!@\=:]:_
MX6%J7_0A>)ORL_\ Y)H_X6%J7_0A>)ORL_\ Y)H]G+^F@^NT?/\ \!E_D>!W
MGAGQGX6UG7+CP[J/BZ]O-/\ %\-AI-OJFLWUU:M9O8H["199&66/SG;,C[MI
M& R@8KS^V\.^)O$/@JTG\0^,/%6M"'^R;K7M'&F:Q:36UTNH6[32^>UW)M=%
M$X\JU5$(PZJ-BU]>?\+"U+_H0O$WY6?_ ,DT?\+"U+_H0O$WY6?_ ,DT>SE_
M30?7:/G_ . R_P CY7\6ZQXWU;X@7\NFZOXN\*6TMWK.GW"V0U75);: 6LPM
M[PQN5MES(BM%##&6P%/G%F(%_2X]9OG\-7FHV7B/58O#OB^9[+4+#5-6D2_C
M?39=A6.[8RQ_O D925Y45G8"3:[+7TS_ ,+"U+_H0O$WY6?_ ,DT?\+"U+_H
M0O$WY6?_ ,DT>SE_30?7:/G_ . R_P CXKM(O%7BK4"^MS>+#X9FL=%U.YL8
M=0URX^PSQ:FOG?Z3,4=IEBER_D1PIP,(?+##U6VO->D\::DOC?5/&]AX<7[<
M=%?19KY9'O1JEQE6$/+@0"U$22 Q%6?Y3V]__P"%A:E_T(7B;\K/_P"2:/\
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M]S]-_M+#_P![_P  G_\ (F;16E_9$/\ T%;+_P B?_$4?V1#_P!!6R_\B?\
MQ%%P_M+#_P![_P  G_\ (F;16E_9$/\ T%;+_P B?_$4?V1#_P!!6R_\B?\
MQ%%P_M+#_P![_P  G_\ (F;16E_9$/\ T%;+_P B?_$4?V1#_P!!6R_\B?\
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M7_0K^)?^_-K_ /)%'U'$_P#/MA[_ /S[G_X!/_Y$]JHKQ7_AJG0O^A7\2_\
M?FU_^2*/^&J="_Z%?Q+_ -^;7_Y(H^HXG_GVP]__ )]S_P# )_\ R)[517BO
M_#5.A?\ 0K^)?^_-K_\ )%'_  U3H7_0K^)?^_-K_P#)%'U'$_\ /MA[_P#S
M[G_X!/\ ^1/:J*\RD^.4<3;6\&>)@< _<M.A&1_R\>]-_P"%[0_]";XF_P"^
M+3_Y(K+ZO5_E,?;+^67_ (!+_(]/HKS#_A>T/_0F^)O^^+3_ .2*/^%[0_\
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MW$;,6WS1,O*KC< (PJ@@'T-X=_:F^$?BRYNK?1_B'H%_-:Z:VKSK#>*?+M%
M+2MZ  C(ZCTKG]6_;6^$&G>#[+Q7:>+;36O#<^KQZ-/J6FR(\5E,\;2!I]S*
M50*AY )Z8!KQS3OV-/B3X6L?"%QX6\0^&] \0Z!IWBF&._C\QPMSJ$J26K*I
MAPP780Y8?+G*K)TK*L?V/?C9;MJFO3ZQX)O/%]SXDTGQ+&+R]U"YLS):V\\<
MD3F6-I,%GC*E2  6PJ;%5@#[,\#>/?#OQ,\,6?B+PKK%IKNB788P7UE)OC?!
M((SZ@@C!K?KR7]FCX4Z[\)_ FI6WBBZTNX\2:UK5]KNH)HBN+&":YF+F.$N
MS*./F8 DDDCO7K5 !1110 4444 %%%% !1110!Y/X5_:&L?$UMH5_/X2\1Z'
MH>N7 M;#6-1%FUO+*Q8(I$-S)(FXJ0"Z*,X!() KJ+CXP>"[2QM+R?Q)8Q6M
MW8SZG!*\F%DMH61)9!ZA6EC7URX SFO*_ ?PH^(T7ACPAX-\267A?3O#GA^]
MBO7U+2]8N+VZOO)E:2*/R'M(5ARQ0LWF28"D '=N''M^R_\ $*[N?"\<]YX9
M@MO!^GWEKI,J75Q(]_(=0LKRV>X0PJ(5;[(4=4:0ID,I?.U0#VC5/CYH<?\
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M;PKX:UJY\UYK.[U&6+2?,@:$PZ7$S+:PA& (50SXR!]X^M 'LM%%% !1110
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MJMW:IJ>;2WTJTU?^T@ UO+'<3SP1QI@ES+YEM("FS/*CDY \/C^$WQ&\ ?\
M"%WD>E>'M4UY;[1K9;)+^X:S7[)IMQ;R/)<?9=T2ME2K^4V"<$=S+>_LF^+[
MS5KS7Y-3TO\ M6:*QO?L5IJ=Y8Q->1W^H74\ N84$L<6R^5$F4%RR%C$!\I
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M&4Y7>WWL!L+G:OJ- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,?HY5_,@^LS_P"?4O\ R7_Y([2BN+_LWX@?]!WP_P#^"J;_ ./T?V;\0/\
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M1_9OQ _Z#OA__P %4W_Q^CE7\R#ZS/\ Y]2_\E_^2.THKB_[-^('_0=\/_\
M@JF_^/T?V;\0/^@[X?\ _!5-_P#'Z.5?S(/K,_\ GU+_ ,E_^2.THKB_[-^(
M'_0=\/\ _@JF_P#C]']F_$#_ *#OA_\ \%4W_P ?HY5_,@^LS_Y]2_\ )?\
MY([2BN+_ +-^('_0=\/_ /@JF_\ C]']F_$#_H.^'_\ P53?_'Z.5?S(/K,_
M^?4O_)?_ )([2BN+_LWX@?\ 0=\/_P#@JF_^/T?V;\0/^@[X?_\ !5-_\?HY
M5_,@^LS_ .?4O_)?_DCM**XO^S?B!_T'?#__ (*IO_C]']F_$#_H.^'_ /P5
M3?\ Q^CE7\R#ZS/_ )]2_P#)?_DCM**XO^S?B!_T'?#_ /X*IO\ X_1_9OQ
M_P"@[X?_ /!5-_\ 'Z.5?S(/K,_^?4O_ "7_ .2.THKB_P"S?B!_T'?#_P#X
M*IO_ (_1_9OQ _Z#OA__ ,%4W_Q^CE7\R#ZS/_GU+_R7_P"2.THKB_[-^('_
M $'?#_\ X*IO_C]']F_$#_H.^'__  53?_'Z.5?S(/K,_P#GU+_R7_Y([2BN
M+_LWX@?]!WP__P""J;_X_1_9OQ _Z#OA_P#\%4W_ ,?HY5_,@^LS_P"?4O\
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M^(HN'UVI_P! \_\ R3_Y(S:*TO.TG_GUN_\ O^O_ ,11YVD_\^MW_P!_U_\
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M)\C6_P#G\L?_  &;_P"+H\C6_P#G\L?_  &;_P"+KR[^1XWUVI_T#S_\D_\
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M;2Z_/?-JJ:Y)I\NKR_V=+>I&J1SO; B-G0(-K8R#7NE !1110 4444 %%%%
M!1110!\\>"OB%XX3P+X&\;ZIK\&KVFNZC!97FDM81PK$D\K1*T3I\VY6V'YL
M@C=T.")K[]K%+/3O!DR^%9)[KQ3I%U?V=LE^!BXCN[2UAMRQC VR/>*3)QL"
MD[6Z5VGA?X Z)X7.BPC5]<U33-%G^TZ=I=_=(UM;2_-M<!$5F*[VQO9@"0<9
M (R1^RKX+,T+RSZS.EI:W-GI\3Z@VW3HYIXKC_1\ %&26")T8DL-H&2   #C
MO%GQZ\5R>(-"\-2V<WA37H]9GT[6(- @;7<H+ W4+V[-#&S*P*Y)B4C##'0F
M;PS^T3XIO=,CTC2_#L?C+Q9;G4[N[AO;@Z,\=C:3B-=Z&*3%U(9(PL6U4/S,
MTD8P#WDG[/>BF:UOHM;UVVUZ"_DU)M<CN8S=S3/!]G.\M&4*^5A0H4  #%)>
M?LZ>&KNVAVZAK=IJ>R[BNM8M+[RKR^BNBIN(YG"X*L8XR-H4IL784YR >=ZA
M^U#XB\9:9X?U[X>^&K2[\)7^L:?I_P#:>HWYAN96GC24I]F$3!(R)$3S3)N5
ML_NR!N/J/PD^,*?%J%9[727L((],M+J[:6<.UM>3>9YED0!R\00%FR/]8F!U
MQ23]F_PC:7^G2:<=0TC2["\M=0AT.PN1%8_:+>-8XG,>W/"1H-N[;\H.,\UJ
M_!OX?2^ /#^I_;+2SLM6UK5+G6+^WT^Y>Y@CFF?)5)72-G  ')1>_ H [ZBB
MB@ HHHH *X?XT>+=0\#?#R]UC2VC6]BNK*%3*FY=LMW#$_'^Z[?C7<5P/B_X
M*^'_ !KXKBU^^DOHKGRK6&[M[:XV07\=M.T]NDZ8.X)([L,$9W$'(XH \I\;
M_MA3>!O$OB*PN/#&F7]EIUGJUQ;R:?KYGN6EL;5[@QW,:VWE0>8L;8"S2NN5
MW("2!:U;]JG6O#VBZX^K^"K'3-7TTV-R\<VMRO8V]C=12RI<75S'9LT)7[/,
MKJL4BA@N)&#%AT^L?LK>#]>AN;:]O-;ETZ0:BL5@+_;!;"_CECN]BA>2XF<@
MON*G[I4%@>CU#X+:3=:Q?ZM9:KK6B:I>PV4$MWIE[Y9*6HF6)2I!1@1<2;@Z
ML#\IP"H- '#V'[35U>>-_"VB2>'=+LK/6+>U9[RX\0)F2>57+)8LL)@O%CV<
MD3QN<G;&<8/+VG[;1O\ 0KS7+/P/<:EI$]I]MT:2SNY=]S'YT<86Y\RW2.W>
M195>,+),K ,&:,@9]/L/V>?#VFKI5O#J>NG2M/D@N!I,NH&2UFN(I#*L[JP)
M#F0[VV%%9@"0:2W_ &=?#=OH\FBKJ.NGP\!MM=%_M%EL[-?.24+'& ,@-&H4
M/OV#(3:": -GX7>/]3\:IXAL]<T>ST/7-"U'^SKRVT_4&OK<L88YD:.9X86(
M*3+D&-<'(YZUW-8?A_P?IWAK5/$&H62R"XUR\6^O"[[@91#'"-H[#9$G'KFM
MR@ HHHH **** "BBB@ HHHH **** "O*_P!H[X@>)/AOX%L-4\*VT-[J\NKV
M=J+29-WVA'?YXEY&&8#:#G@D&O5*P_%?@_3O&4&G0ZBLC)87\&I0^4^W$T3;
MDSZC/44 >!_$+]JJ\\/>+3J6A6]KK7@:T\,7VK':3')?W$<-O.JK*0=B"*XB
MYVG)D;/W:V/BY\??$'A[Q#K&A>&]-M!?Z3=1PF6^N"([H2:;<W2@XC8Q[6A4
M9 ;/MFNJ/[,G@-M'?2FL+EM/>+5(6A-RW*7Y0W SU&/+0)@_*% '2I++]G7P
MS#?7-]?WFL:W?W4\=Q<76I7F]Y62VDME!VJH \J5Q@ <X/6@#SKP?^T?XUU#
M1M%@D\*6&L>*=2CT>(6RZN;>R22[LI+EI3+]F+JH$>2-C$%L#..:L_[76H:?
MXGU6WN]$BBEATS3X(M%>=BL>JR7^H6TX:YCB=C !9A@ZQ%MHSLR=HZ[5?V8K
M2VB\,0^']:U.P.GWUE+<W[WF+KR+6UF@A$9$94L!(H(9<$ YYZ[2?LR^#8G:
MXB.IQ:D8+:,:FMX3<K+!<SW*7 <@_O3+=3%B00P;:5V\4 5Q^T#+#\!_%'Q#
MNO#4L=YX>@NI)])6:18[AX1G]Q-)"C-&XQM=HE/)RHQ6%!^T5XPB\17VEZC\
M/=.L_P"S=6M=(OI8O$9EVRW4:O:F(?91O'SJ)=Q39GY#-SCTN_\ A9INL_#S
M6/!^K:AJVL:?JT,L-Y<WUX9+B19!AL-C"#'144*.PIMW\(O#][JVJ:C*EQ]I
MU+4[/5IR)L SVRHL1 QP,(N1WH \SG_:SA_X1*UU6#PV3>36]C$]I/>L$M]3
MN'E5K*1XXI&'DB%V=U1C@IA#NXQ5_:MUB3Q'I,;>'#$USH^H#^Q@[JEUJ27^
MGVMMY5S+%&WV=OM9)D,0(&3L)7:>]\*? :R_X1'5+;7+>/2]8U77I/$DLFB7
MSR?8KPN"C0SO&A;:% ^:, [F!4@\W]1_9Z\-ZW)%<ZK?ZWJNI164]E'J-WJ+
M-<1^;<07'F(P ".DMK"R; %7:?EY.0#CM3_:1\5V>HIX=M_ .G7/C2*[N[6]
ML&\0LEC"(;6.Z$B7/V0NZO'*H&85(;((Q\U4]"_:TO=8\,W>JW'A/3M&\[0M
M.\2:2=3\1)#;RV5X\B*;J4P_N)%\HDI&LY(90NXD@>DZ1\#?#NE:C%J32ZA?
MZL)KJXFU"[N TUS)/"D#M)A0.(XT50   HXK)7]F7P?!8Z+;VKZG92Z-I6GZ
M1I]U#=#S8(K-W:!AN4@N#(^2000>E &O\#_BN_Q@\(7.KSZ7'I%W::A<:=<6
M\%R]Q%YD38+1R/%$[*001NC0^HKT*N6^'WP[TWX;Z9?6>FW%]=B^O9=1N9]0
MN#-+)/)@R,6(&,D9P, 9P   !U- !1110 4444 %%%% !1110 4444 %%%%
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M U'M:G\S^\/[/P?_ #YC_P" K_(^]/\ A2'@S_H$R_\ @?<?_'*/^%(>#/\
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M_0)E_P# ^X_^.5W=?,GQP\$'QU^TGH%K_P *]\&_$00^$KF7[%XTN/)@M_\
M3(1YD9^QW67YQ]U>">>U:*I-*R;.*>"PM23G.E%M]7%?Y'L'_"D/!G_0)E_\
M#[C_ ..4?\*0\&?] F7_ ,#[C_XY7R0?AM<?#WXY:8NMZC!J^I^'M'\-0VOV
MBWBN+;3DN=5O%DBM6FC9XT1$1%8,K%4!/10O03?&C5KK0O$_B;P;\4HO$6GO
M>6VG6.FZEJMFIMK,7*I<ZG+)#;2/"ISL4M$ZHF'();Y7[6I_,_O(_L_!_P#/
MF/\ X"O\CZ7_ .%(>#/^@3+_ .!]Q_\ '*/^%(>#/^@3+_X'W'_QRO%?AMXP
M\<^)?B#X$TC4O&]C=:7.=:NY'\-:A'J4=W';G3_)BENFLX0Y5IY@3'&H(8#.
M1D?4M'M:G\S^\/[/P?\ SYC_ . K_(X3_A2'@S_H$R_^!]Q_\<H_X4AX,_Z!
M,O\ X'W'_P <KNZ*/:U/YG]X?V?@_P#GS'_P%?Y'"?\ "D/!G_0)E_\  ^X_
M^.4?\*0\&?\ 0)E_\#[C_P".5W=%'M:G\S^\/[/P?_/F/_@*_P CA/\ A2'@
MS_H$R_\ @?<?_'*/^%(>#/\ H$R_^!]Q_P#'*[NBCVM3^9_>']GX/_GS'_P%
M?Y'"?\*0\&?] F7_ ,#[C_XY1_PI#P9_T"9?_ ^X_P#CE=W11[6I_,_O#^S\
M'_SYC_X"O\CA/^%(>#/^@3+_ .!]Q_\ '*/^%(>#/^@3+_X'W'_QRN[HH]K4
M_F?WA_9^#_Y\Q_\  5_D9OA_P]8>%]-2PTV%K>T5BP1I7DP2<GEB3^M:5%%9
MMMZL[HQC"*C%62,CQ+X4TOQ?91VFK6[7-O'()559GCPV",Y1@>A-<W_PI#P9
M_P! F7_P/N/_ (Y7=UYM\?=#O[WP*-<T6U>]U_PO=1Z[86T0R]PT.?,@7_:D
MA:6,>[BJ4Y15DSFJ83#5I<]2G&3[M)E[_A2'@S_H$R_^!]Q_\<H_X4AX,_Z!
M,O\ X'W'_P <KP'5_B+;RZ%=_$[3M3N;&7QWK$6G:+J2WEOI]O\ V;;1R^1Y
M]U<QN+>!V\^7*QN[&10JMFN5\ ?M >-9YO U_P"(/%L6HVUS+;V-QI6DWUO'
MJ7F_VA<P-*UK-;(;R%E2$,\312)L=O)[57M:G\S^\R_L_!_\^8_^ K_(^J/^
M%(>#/^@3+_X'W'_QRC_A2'@S_H$R_P#@?<?_ !RO%O 'Q@\37/BGP^\6J:AX
MSUF^74CXA\&68M%DT@Q-^YV[S%Y)#!4Q-)^\#%ATJ7Q?\7/$D?BW66?6+[PM
MX@M-1TJ#1? MT+5I-2MIO*\YW"&0RDEYU+12%8_)!/?)[6I_,_O#^S\'_P ^
M8_\ @*_R/9/^%(>#/^@3+_X'W'_QRC_A2'@S_H$R_P#@?<?_ !RO"8OBOJS^
M#Y-3E^)$UOXFN;@P:WH0CMG'A^ WJ1RS!?+W0^5&3AI2RL"7P0*Q_&GCL^'/
MB=H^MZ#X[?Q/8V>BNL^O.8)5CM#K>EBX#21H(V18FDRX' SSD9H]K4_F?WA_
M9^#_ .?,?_ 5_D?1W_"D/!G_ $"9?_ ^X_\ CE'_  I#P9_T"9?_  /N/_CE
M?-GQ$^/NOO+K>JZ1X\LU\-66N7T"1V>HVEK=75NEM:,ALI9XG@N#&7G;R6=#
M+N&)!MP=#Q'\:O$O@2#6O&>E13W-E<ZQ-I*:))8Q0O->W6GVKZ>TP5=X<7 6
M)LDX$YSG8N#VM3^9_>']GX/_ )\Q_P# 5_D?0?\ PI#P9_T"9?\ P/N/_CE'
M_"D/!G_0)E_\#[C_ ..5X%X8\>?$ZU^*\'AS4_%N@^9I>JVVF36NJ:SY-YJ5
ML(8_,G2P33R7:0EW$BSJ@/!"A2*]%\<^-Y[;XS7FCZQXZD\"Z9::?87&CVZ+
M"!K$TD\HN%_>(S3;?+A3RXB&42Y/WE(/:U/YG]X?V?@_^?,?_ 5_D=Q_PI#P
M9_T"9?\ P/N/_CE'_"D/!G_0)E_\#[C_ ..5\Y:IXR\7#0='UQ_&,$.K7DWB
MD0:EK=M"+?3$MY)(XMKI"SQ(%4;GPW3+!@"#2F^//C6]T+P_9V.LVUE:MK&H
MV6J>(-9\3VL-CYD44+P16VIPV,T<D<@E=@7@C?,;(VTC!/:U/YG]X?V?@_\
MGS'_ ,!7^1]-?\*0\&?] F7_ ,#[C_XY1_PI#P9_T"9?_ ^X_P#CE?/_ (4^
M+WC6R^('@RW\3^+]-UR/4A96[V?A748=ZNZ$>9):7%M%+-!(?F,\+@K_ ,\@
M 370_&'Q+KMC\?+S2M&U4Z&;O3/#-N]]:VD#7(CFU/44E42.C$@J@ !R%))
M!)R>UJ?S/[P_L_!_\^8_^ K_ "/7_P#A2'@S_H$R_P#@?<?_ !RC_A2'@S_H
M$R_^!]Q_\<K@M+\8>(W^!7Q"F'B>&UUG0]0U/3[37]:"JD20RD)).T<9 PIP
M7$9 QN*G!!\>NOC9XGN/#VFZAIL\NHZ[IDVN6QO)6L]8C!2WA;S;.Z@B3SHE
M1RWW(W)!1T^7%'M:G\S^\/[/P?\ SYC_ . K_(^GO^%(>#/^@3+_ .!]Q_\
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M_P!)_P#%5LT4<J[!_8^6_P#0-#_P"/\ D8W_  B&D_\ /LW_ '^D_P#BJ/\
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M (6OHW_/GK?_ ()[G_XBC_A:^C?\^>M_^">Y_P#B*[.BM+P[?C_P#B]GBO\
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M^C?\^>M_^">Y_P#B*/\ A:^C?\^>M_\ @GN?_B*[.BB\.WX_\ /9XK_GXO\
MP'_[8XS_ (6OHW_/GK?_ ()[G_XBC_A:^C?\^>M_^">Y_P#B*[.BB\.WX_\
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M%GXJZ*R[39:T5Z8.C7./_1=-/Q1T(A1]@UC"_=']BW/'T_=UVU%%X=OQ_P"
M'L\5_P _%_X#_P#;'%CXJ:*#D66M ^O]C7/_ ,;II^*6AEMQL-9+>O\ 8USG
M_P!%UVU%%X=OQ_X >SQ7_/Q?^ __ &QQ(^*6AA]PL-9#=-W]C7.?_1='_"T-
M"VL/[/UC#<D?V+<\_P#D.NVHHO#M^/\ P ]GBO\ GXO_  '_ .V.)_X6AH1V
M_P#$OUCY>1_Q);GC_P ATO\ PM/1-^_[#K._^]_8USG_ -%UVM%%X=OQ_P"
M'L\5_P _%_X#_P#;'&?\+7T;_GSUO_P3W/\ \11_PM?1O^?/6_\ P3W/_P 1
M79T47AV_'_@![/%?\_%_X#_]L<9_PM?1O^?/6_\ P3W/_P 17&_&?XEZ5J7P
M>\=6D5KJZRSZ#?Q(TNE7$: M;N 68H HYY)X%>RUPWQW_P"2'_$/_L7=1_\
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M_(^R_OE?[:G]V3_O@T?;4_NR?]\&K%%>M:??\/\ @GM>QS'_ )_Q_P#!;_\
MDRO]M3^[)_WP:/MJ?W9/^^#5BBBT^_X?\$/8YC_S_C_X+?\ \F5_MJ?W9/\
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M\9_S]C_X _\ Y(N?#SXEZ5:?VAOM=7.[R\;-*N&_O>B5V/\ PM?1O^?/6_\
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MLF_^/4?V?\0/^@UX?_\ !9-_\>HY%W0?69_\^I?^2_\ R1VE%<7_ &?\0/\
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MH6/B%);N;4GGB>XTV:.XE\NT)!RUNT<HDC"9V.9]P!DS7J_]G_$#_H->'_\
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M"VBUS4;2XNEU&^>T\C?Y06*)G$4I/EED7N^6KZ/_ +/^('_0:\/_ /@LF_\
MCU']G_$#_H->'_\ P63?_'J?(NZ,_K,_^?4O_)?_ )(\8E^#?B3PWXRL=>L/
M"\>HZ7I4NC3C1K*:VC>Y\C3[JUD$2R.D8:-IHB-[("$X;@5Y3+\)_$DOC3QW
MX0A\$VESKGB/P EO Z7< C\,"]U75)8U+,03'&2CMY&XB2W0(K AE^O?[/\
MB!_T&O#_ /X+)O\ X]2?V;X_W;O[9\/;L8S_ &9-G_T=1R+N@^LS_P"?4O\
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MQ)/X:>TU6TOM/UZ>\N/$D?F636\+Q6SL[@LJ&+S5G+DY4OM,G)H]K'L_N?\
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MK\/?&EI\1?!&B^)K*":UMM3MDN%M[D 2Q$CE&P2-RG(."1QP37C.K?!^YO\
MQ)/X@L] \0^'M0ENY]0$FCZW!&\1EAB@N J%2OF.(8RJDE3RVY&XKU;X::;<
M^'-!L_#Z^'8_#VE:5;1VUM&E[]I# #@*Q&Y@%QEGY+$]<;BU44G97^YF=3!U
M*47.3C9=IQ;^Y-L[&BBBM3A"BBB@ KQSXV^.?%/A'7M/6U?4-'\)FPFGN=<T
MO1&U>1+H2(J121)ED3:S-N"G)7&Y<?-['7&>*OA=9>)/$L'B*VU75?#NO1VG
MV![_ $B9$:>WWEUBD21'1@KEF4E=R[FP0&8$ \?\1_M8WO@?1/#=U?6/AGQ
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MK@0Q1@A%5<!2W)S(P,C<;G; QUM !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N&^.__ "0_XA_]B[J/_I-)7<UPWQW_ .2'_$/_
M +%W4?\ TFDK2G\<?4UI?Q(^J/PMHHHK]$/U,**** "BBB@ HHHH ]]_9=_Y
M GQ&_P"P?:?^E25WU<#^R[_R!/B-_P!@^T_]*DKOJ]S+?X<_\7Z(^BRG^%/_
M !?I$****]<]L**** "BBB@ KVSPU_R3/PU_UTN__1@KQ.O;/#7_ "3/PU_U
MTN__ $8*\O'_  0]?T9X^9_!3_Q?^VR)****\L\4*ZWX3?\ )1=#_P"NQ_\
M06KDJZWX3?\ )1=#_P"NQ_\ 06KFQ/\  GZ/\CEQ7^[U/\+_ "/K.BBBOS4_
M)@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y_Q#;>)YKN,Z)?Z7:V
MP3#I?6LDKE\GD%9%&,8XQZTTKLSJ3<(W46_3_@V,SXE>";OQR?#%M'-"FG6.
MM6^I7\4K$&:.$,Z*H .3YHB;!P,*>>Q3Q=X*OM>\?^"=<M9K>&VT1[UK@2$^
M8WG6YB38 "#ACDY(X]>E'V#X@_\ 08\/?^"Z;_X]1]@^(/\ T&/#W_@NF_\
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M_!=-_P#'J/L'Q!_Z#'A[_P %TW_QZGR+NB/K,O\ GU+\/_DCM**XO[!\0?\
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M ,>H^P?$'_H,>'O_  73?_'J.1=T'UF7_/J7X?\ R1VE%<7]@^(/_08\/?\
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MOY'C?7JG_0//_P E_P#DC7KK?A-_R470_P#KL?\ T%J\[\G7/^?JQ_[\/_\
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MQ7^[U/\ "_R/K.BBBOS4_)@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLO\ X4?X-_Z!EQ_X,KK_ ..5W=%:*I-*R;.*>!PM23G.E%M]7%?Y'"?\*/\
M!O\ T#+C_P &5U_\<H_X4?X-_P"@9<?^#*Z_^.5W=%/VM3^9_>1_9^#_ .?,
M?_ 5_D<)_P */\&_] RX_P#!E=?_ !RC_A1_@W_H&7'_ (,KK_XY7=T4>UJ?
MS/[P_L_!_P#/F/\ X"O\CA/^%'^#?^@9<?\ @RNO_CE'_"C_  ;_ - RX_\
M!E=?_'*[NBCVM3^9_>']GX/_ )\Q_P# 5_D<)_PH_P &_P#0,N/_  977_QR
MC_A1_@W_ *!EQ_X,KK_XY7=T4>UJ?S/[P_L_!_\ /F/_ ("O\CA/^%'^#?\
MH&7'_@RNO_CE'_"C_!O_ $#+C_P977_QRN[HH]K4_F?WA_9^#_Y\Q_\  5_D
M<)_PH_P;_P! RX_\&5U_\<H_X4?X-_Z!EQ_X,KK_ ..5W=%'M:G\S^\/[/P?
M_/F/_@*_R.$_X4?X-_Z!EQ_X,KK_ ..4?\*/\&_] RX_\&5U_P#'*[NBCVM3
M^9_>']GX/_GS'_P%?Y&;X?\ #MAX7TU;#38G@M58L$>9Y3DG)^9R3^M:5%%9
MMMZL[HPC"*C!62Z&1XE\*:7XOLH[358'N((Y!*JQSR1$-@C.48$\$\=*YO\
MX4?X-_Z!EQ_X,KK_ ..5W=%4IRBK)G-4PF&K2YZM.,GW:3.$_P"%'^#?^@9<
M?^#*Z_\ CE'_  H_P;_T#+C_ ,&5U_\ '*[NBJ]K4_F?WF7]GX/_ )\Q_P#
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MW11[6I_,_O#^S\'_ ,^8_P#@*_R.$_X4?X-_Z!EQ_P"#*Z_^.4?\*/\ !O\
MT#+C_P &5U_\<KNZ*/:U/YG]X?V?@_\ GS'_ ,!7^1PG_"C_  ;_ - RX_\
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J8'$D;F_N& (Z<&0@_0BNRHHJ')R^)W.FE0I4$U2@HI]DE^04445)N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gmab-20240502xex99d1007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  # -8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[Y?\ 92^%
M,C%CX1A!_P!F[N /R$E.C_96^%L0PGA94'7"WUR/_:M%%;^WJ_SO[V>1_8^6
M_P#0-#_P"/\ D._X9;^&'_0L_P#D_=?_ !VHC^RC\+22?^$:D_\ !I>?_'J*
M*/;U?YW][!Y/EKWPT/\ P"/^1*O[+?PT10JZ!<*HZ :O>@?^CJBN_P!F'X;Q
M6TKKH5R&520?[7O?_CU%%'MJO\S^]BEE&7)/_9H?^ 1_R,'_ (9U\ #_ )@]
MS_X-;S_X[4W_  H'P1_T#K[_ ,'%[_\ 'J**T]M4_F?WGE++,"MJ$/\ P%?Y
M%'5_@5X,M;4/%87RMN S_:]X?7_IM60GP=\+1L&2VOU8="-6O ?_ $;116D:
MLVOB?WG%6R_!J>E&/_@*_P B7_A4WAS_ )YZE_X.;S_X[67JWPRT*VE01#4E
M!7)_XF]X?_:M%%:1G.^YR5L'AE"ZI1^Y%2/P%I4)/ER:HF>NW6+L?^U:?_PA
M.G?\_&K_ /@ZO/\ X[116O-+N</U:@OL+[D8.H>'((+R5$O=755/ _MB[]/^
MNM1II/EKM34]:0>BZS=C_P!JT45=W;<\N5*FI.T5]P[^S7_Z"NM_^#J[_P#C
MM<WYM]_T&M;_ /!Q=?\ QRBBMH:G%B(J-K(E&HZJH 'B'Q  . !K5W_\<J#4
M-7UB"SD=/$?B!6 X/]M7?K_UTHHK1)'%*4E%ZF(/%?B)2"/%'B $<@C6;K_X
MY4O_  FWBG_H;O$O_@[N_P#XY116G*NQYRK5%M)_>9^L_$#Q=:11F+QCXE4E
ML'_B=71_]J5EI\4O&T;9'C/Q&3_M:Q<D?J]%%:QA&VQP5<374])O[V2?\+9\
M<?\ 0Y>(/_!I/_\ %UD:M\:/']M=!(_&WB!5V@X_M.8^O^U115JG"^R..OC<
M2H7567WO_,JQ_';XBQ9V^-]>.?[U_(W\S1115^SA_*ON.'^T,9_S^E_X$_\
#,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gmab-20240502xex99d1009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !) )$# 2(  A$! Q$!_\0
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MJ%N<B9O'<;%!:^'IU4X$OVBXC+CUV>6VWZ;C]:NKHFKZBV=5U=4@/6UTR(P
MCT:0LSGZKLSZ5T(I.U/F["(+#3[;3(!!:P1V\(Y"1K@9/4_7WJU2=Z6IW*"B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gmab-20240502xex99d1010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% +,# 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmab-20240502xex99d1011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ] %H# 2(  A$! Q$!_\0
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M5D!'/,EO$TCG"J,DUC2/J6MR-'#NTNQQS.PS/)_NJ>%'N<GV'6MPC-& *$[
M9^E:!9:.'-O%^^D_UD\A+RR?[S'DUH#BEHI/7< HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmab-20240502xex99d1012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  H (H# 2(  A$! Q$!_\0
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M/:SH$T5S<S-EHK2ZA*RQRD'EX6P&&>2K$<,#CG8/B)H'B'4+?[3X/:;Q5-&
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E&.()\D=Y"568@XP#)&\;$>L1/5C7HIHHK2?1D1ZCJ***S+/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmab-20240502xex99d1013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J ,P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**0G%
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M ,O)?B3%2LTM"#P9X\N/$6M7NC3Z<4NM,MH'O;R$_P"C+<2#<85R=VY1@D$
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J@HHHH 3 I:** $P*6BB@!*6BB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmab-20240502xex99d1014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ - # 2(  A$! Q$!_\0
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MUI 28[6&,MU*Q@9^O%9NL>#M'UZ]LKN^L8Y[BS),,F2I4$@D'!&Y25!*G()
M..*VZ6A2DM4P$P*,4M%(!,48I:* $Q1BEHH 3%4-9TB'6]-GLYRRQS(4+)C<
MH(P2"0<'\*T**$VM4!C^&/#.G>$-$MM)TFV%K86X(CB!)ZDDG).3DDG\:U\<
MT#-'6DVV[L"MJ&G6VJV4UG>V\5W:S*4E@G0.CJ>H(/!'L:DBA2&)(T14C50J
MHH "@<  >E3447Z %%%%,#C?$UU]L\<>%M'.[RCY^HR#:2&,054!.,##2AN>
MZC%=CBFD#.>]./2G*2:2ML M%%%(!.G-><>!=WBWQGKOBABLEG%*=.L&Z_+$
M2KD>Q8N??(]*]'/2J6FZ79Z-8I:6-M%:6L98I#"H55R23@#U))_&M(348M=6
M!EV7@RQM/%VH>)"\TVHWD,5O^]?*0QH#A47'&2Q))R23Z<5T)XH!XI:AMRM=
?@%%%%( HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmab-20240502xex99d1015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X '0# 2(  A$! Q$!_\0
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M<TY)RO$WBFEJ>,^&I-0U4^%O!UW:SK?^'+SS=1N3;LL(@MPRVS*Y&UC+F)@
M20!)G!%>R@ BC;S2YXJ93YM@C&PM%%%26%%%% !1110 4444 -/2O+O@MX7G
ML]+U^XUG3O)O9O$NH74"7,)W1()3'$R%L\%%!##C#8'%%%:)M0:1FU>2/4Z*
:**S- HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmab-20240502xex99d1016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !* 0X# 2(  A$! Q$!_\0
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M*&SDDA1BQ@>13CRB3GIGMQC-?2%% 'R[X]_9S\>Z#\2M&\1_">Z\-Z78:7I
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M]:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y_Q[X*L/B%X5O]"U$,(+E/EEC.'AD'*2(1T96 (/M7044 ?/R_%KXH
M?#"U?1/$WPTU?QU=P)Y=CK_A4K)#?@<*UQ&WS6[D<L?F&>E='\$/!OB8ZSK_
M (\\;V<6F^)==V11:9'*)?[/M$Y2$N.K$G)QQ7KI')I: "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gmab-20240502xex99d1017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  V '0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4CR*P+J\
MOM7OY;/3I5M;: [9[PC<V_\ N(#QG'5CTZ8/:[XAU&33],D:  W4I$, /]]C
M@?EG/X54BOM*\(VMII\MT(FQ@%\LS$GEV('&6.2QXR:J*Z]0*UYI&H:/&U[I
M^H7-W+'\\EI=OO291U"G'R-Z$<9ZBN@LKJ.]M(;B(DQR*&7(P<&GD[AUXK"\
M&7!?3;FW+AVL[R>W/S9P Y*@_P# 2M._-&[Z".AHHHJ!A129I: "BBB@ HHH
MH **** "BBB@#EO$6HI!KEIYX)M;&VFOY.,Y<81 /?#/^(%5-2LAIW@W6-0U
M.15O+B!IKF4C<(QCA!_LJ.!Z]>]5?$85_B+IEF[,?[0M  G\)6&3>Y_\>0?C
M6IX^>.XTRSTI@S-JEY%:@+_=SYCGZ;(WKIBK.'WDE&PBU(ZWH=]/(VZ[67S8
M<_+#"(P47'KG!)]2>V*H^%M:N_\ A)+PP1Q?V5>ZM<PJR#<SE(U#2$]AN1EQ
MWQGTJ]XSU?\ LG5('B0//':M% BCDRRNJ(!_WR3^%.\.:4FC7NBZ4[@RV=F\
M\A9N6DD;GZGAS5_8<FM_Z_R"^MCMJ1F"@D\ <Y-&>*P?&=P(]$>+S!&;F1+?
M<3CAF&[_ ,=S7'%<S2*+^AZPFN6 NDAD@&]T\N4 ,-K%><$]<9_&M"LCPS&T
M.AVN4V-*#,5]-[%L?^/47?B."VOC;!7F,17[0\8&VW#="Y_SQSTJFKMI"1KT
MAX%4M3U:#2K>.69CMDFC@7:,DL[!5'YFI8[^":ZFMDF1[B$*TD8.2@;.W([9
MP?RJ;=1DZNK$@$''7!Z4I.*XS6==G@U'46TN>QM(+*,2WUS<JT@9L':@"D8/
M')Y/0 5)XBUTRCP[%;WD4<][,D^8WX=%7<<=R"Q0=/XJU5-NPKHZ[=2@YKC?
M#_B=Y?[7$5O>Z@%OI1 XC(1D&.CMA=H;<.">E2^&O%X,YTG6KB&SUL,S)"[@
M">,L=K1DXW@# ..A'-'LI:Z;!<ZZBF[O:BL1G!^)1+>>.89[2)Y;W1;+ST10
M<.LKXD3/0DK$,<]0*Q=1\=Q:IX^1K+[*]OIFG"9+B^F,<1EF;!50 6,@5,8Q
MQO/KBO5=G)..37/'1#HVKS7UM:I<6EPQDEA5%\R.4]9$/?=CD=<\^M=4*D-I
M+960K'+:5;7NH>)KOQ5XCTTV%K:P!K"(N'$85#YDK=,$Y8#(! /."<#$TQ5U
M][#6+JW5M0U+4(7N+OK]C@W$PVZL.A(VAL?WVSU%>AR6]SXJ8175G)9:0I!:
M&XP'N3UPR@G">H/+=",==>71[*;3FL'M(38LNPV^P;,>F.E:.O;IKY=%_6I/
M*9'BCQ!-8RVEAI\B'4;J3:N1N$8"ELL.P.,?RS6-XOFN/%45BFE0O=VMG=I<
M74L+#;,@#*T49/#$[N3T '7-=0_A;2I+#[%)I]O+:[@YBE0."WJ<YR?<UI0P
MI;QK'&BQQJ JJ@P /0"N>,XQLTM2K'+)IVO33QZJDD5K<C=&NG3$M%Y)QA68
M='R =P! Z8/6L.V\$:YX@L[NPUYK:PL)+J2>4:?,TDEX2<IO9E7:J_*-O.=H
M' XKTC-&::K..R%8XK5M-@L[: >(=;GNY0X-M';IY+;UZ%$3+,WYCGH*IIH-
MY<7(ETC3[C3-Z;9;R[O"CS#)(W( S,>3R2IK4ETG5-+\2WVJV]K;:L+K8JF:
M4Q36Z  >6AVD%,Y;J.6/7C&A_;FIQR.)- N2BCAXKB%L_@6!J^9VTU^?Z!8S
M;?P"#<QW-U>YN(QM1K6!8MO.>IW,3DGDGN:DLOACX>L;LW26)>YSGS7D8L/7
M'/'T%67\7BWA$EQI.HVXSR&C1L?]\N:NZ+XFT_7GECM)RTT2JTD3H490>AP1
MWJ7*JD]= T&#PAHVS8=-MW0]0Z;L_G4X\.:4/+/]F6>8B&C/D+\A'0CC@UI4
M5CS/N4)C%%+146 *0C-%%,  Q2T44 %%%% %&\LKJ=\PW[VPQC:L:,/KR*S3
MX8O)MGG^(M2?:2<1>5$#[':F:**M2<=@*P^'MBXQ/J.LW/S;QYFJ3C!_X"XX
M]C4J_#S01,TK632NPPWG7$D@/U#,1115>TF^HK(FA\">'H"Y31;'+_>W0*V?
CS%;$%I#;*%AB2)0  $4 8'0445#DWNQDU%%%( HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gmab-20240502xex99d1018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L .8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4!\O2E!W
M#T- ;UI0,4 (V,<TPA<@\YITQQ&3@G S@5YAI.C>([ZW@\6:-KOG7]_'YD^D
MZBS-8R)N.Q$V\PLHXW@')SN![ 'IK<<YI!P>G!KC5^)EI8CR]>TS4?#]POWC
M<6KRV_3DK/&&0CW)!]A6=K?QS\,6-F#IUS)KVHS-Y5GI^FPO)+<RD<(IV[1[
MDG ')JBCT7>.G2@'(Z\&N2^'L'BLZ3-=>+IK4:C=2^8EA9*/*LH\ "+?UD;N
M6/<\<5<UKQ8-)\5>'=#2#S9=5:8EMV/*CCC+%\=^=J_\"I".B3(^GO2LN[K1
MCCBF3S"WA>20A40%B3V I"%Y!]NU(2.?05C>$?$T'C'0+;5[>&6&UNMS0B88
M+(&(5_HP&X>Q%:^W#>H--#0PO^\&!UJ8'/'.:0(,YQ^-*S! 6Z #O0#%8[3G
M%-#9KF+3XD:'J>NQ:3;3S2W,I=8I?LT@@E9!EU24KM8@ G /8^E=*<HN3Q2
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2*&Z&DSP: ''I130>**=AV/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gmab-20240502xex99d1019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20240502xex99d1019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  W $0# 2(  A$! Q$!_\0
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M\-W$.FZBUE Q.G:@IOK%C]T;L&6,>F"=X'HQ_NT =91110 4444 )C-+110
M4444 (W(KD[GPS?I=/#:R01V:.;RUE?)DMY]PR@ X,; R9YS\V*** .L7.!G
,K[4M%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
